



WORLD
HEALTH
SUMMIT

SCIENCE · INNOVATION · POLICIES

WORLD HEALTH SUMMIT
BERLIN, GERMANY
& DIGITAL
OCTOBER 25-27, 2020

VENUE

Kosmos, Karl-Marx-Allee 131a
10243 Berlin, Germany

WIFI

Network: WorldHealthSummit
Password: #WHS2020

DIGITAL

www.conference.worldhealthsummit.org/Program/WHS2020


www.worldhealthsummit.org

SOCIAL MEDIA

#WHS2020

- [www.twitter.com/worldhealthsmt](https://twitter.com/worldhealthsmt)
- www.facebook.com/worldhealthsummit
- www.linkedin.com/company/worldhealthsummit
- www.youtube.com/user/WorldHealthSummit1

Karl-Marx-Allee



WORLD HEALTH SUMMIT
BERLIN, GERMANY
& DIGITAL
OCTOBER 25-27, 2020

SUNDAY | OCTOBER 25, 2020

	SAAL 1 RUDOLF VIRCHOW	SAAL 6 EUROPE	SAAL 10 ASIA	SAAL 2 AMERICA	SAAL 4 AFRICA	SAAL 5 OCEANIA
	PD 01 Page 20	PD 01 Page 20	PD 02 Page 22	PD 03 Page 24	WS 01 Page 26	WS 02 Page 28
11:00–12:30	COVID-19 Driving Effectiveness and Efficiency in Healthcare Siemens Healthineers AG	Overflow PD 01	Developing Antibiotics for Children to Achieve SDG 3 Global Antibiotic Research & Development Partnership (GARDP)	Antimicrobial Resistance World Health Organization (WHO)	Digital COVID-19 Pandemic Response Management Helmholtz Centre for Infection Research (HZI)	Innovations to Improve Pandemic Preparedness Johnson & Johnson
12:30–14:00 Lunch Break						
	PD 04 Page 30	PD 04 Page 30	PD 05 Page 32	PD 06 Page 34	WS 03 Page 36	WS 04 Page 38
14:00–15:30	Multilateral Public Health Partnerships during the COVID-19 Crisis M3 Alliance The Graduate Institute of International and Development Studies	Overflow PD 04	Nursing in the time of COVID-19 University of Eastern Finland	A Call to Action for Health Data Governance Fondation Botnar	Universal Health Coverage Robert Bosch Foundation	Changes in Health Research during and after the COVID-19 Era Berlin Institute of Health (BIH) Charité – Universitätsmedizin Berlin QUEST Center
15:30–16:00 Coffee Break						
	PD 07 Page 40	PD 07 Page 40	PD 08 Page 42	PD 09 Page 44	WS 05 Page 46	WS 06 Page 48
16:00–17:30	A Fast European Response to Pandemics using Data and Joint Investments in Health Sanofi	Overflow PD 07	Bringing the COVID-19 Epidemic under Control Charité – Universitätsmedizin Berlin Max Planck Institute for Infection Biology	Strong Partnerships as a Determinant of Health GHA – German Health Alliance UNAIDS UNITE	Recoupling Societal Wealth and Individual Health Global Solutions Initiative	Translation in the Times of COVID-19 Berlin Institute of Health (BIH)
	KEY 01 Page 50					
18:00–19:30	Opening Ceremony M3 Alliance World Health Summit					

MONDAY | OCTOBER 26, 2020

	SAAL 1 RUDOLF VIRCHOW	SAAL 6 EUROPE	SAAL 10 ASIA	SAAL 2 AMERICA	SAAL 4 AFRICA	SAAL 5 OCEANIA
	KEY 02 Page 54	PD 10 Page 56	PD 11 Page 58	PD 12 Page 60	WS 07 Page 62	WS 08 Page 64
9:00 – 10:30	Achieving Health for All through Digital Collaboration World Health Organization (WHO)	National Responses to COVID-19 MB Alliance Tehran University of Medical Sciences (TUMS) The George Washington University, Milken Institute School of Public Health	Climate Change and Health London School of Hygiene & Tropical Medicine (LSHTM) MB Alliance	Access to Sustainable NCD Treatment & Care Boehringer Ingelheim Pharma GmbH & Co. KG The Defeat-NCD Partnership	Multi Stakeholder Collaboration in Global Health Research German Federal Ministry of Education and Research (BMBF)	Pandemics and Operationalizing One Health German Federal Ministry for Economic Cooperation and Development (BMZ) The Lancet One Health Commission
10:30 – 11:00 Coffee Break						
	KEY 03 Page 66	PD 13 Page 68			WS 09 Page 70	WS 10 Page 72
11:00 – 12:30	Strengthening the Role of the European Union in Global Health German Federal Ministry of Health (BMG) Germany's Presidency of the Council of the European Union	Setting a New Agenda for Women and Cancer Roche			Evidence-Based Decision-Making in Global Health German Alliance for Global Health Research German Federal Ministry of Education and Research (BMBF)	InfectControl—Investing in the One Health Approach German Federal Ministry of Education and Research (BMBF) InfectControl
12:30 – 14:00 Lunch Break			PD 14 Page 74	PD 15 Page 76		
12:30 – 14:00			Climate Change and Health Association of Academies and Societies of Sciences in Asia (AASSA) Inter-American Network of Academies of Science InterAcademy Partnership (IAP) The Network of African Science Academies	Youth Perspectives on Health International Federation of Medical Students' Associations (IFMSA)		
	KEY 04 Page 78	PD 16 Page 80			WS 11 Page 82	WS 12 Page 84
14:00 – 15:30	Pandemic Preparedness in the Age of COVID-19 Charité – Universitätsmedizin Berlin Foundation for Innovative New Diagnostics (FIND) London School of Hygiene & Tropical Medicine (LSHTM) MB Alliance	Radiation Therapy as an Essential Component of Cancer Control International Atomic Energy Agency (IAEA) Varian Medical Systems			NTDs and Challenges of the COVID-19 Crisis Association of Research-based Pharmaceutical Companies (vfa) Eberhard Karls University Tuebingen German Network against Neglected Tropical Diseases (DNTDs) German Society for Tropical Medicine and International Health (DTG) University Hospital Tuebingen	Vaccination and Transmission Control Leibniz Association Research Center Borstel – Leibniz Lung Center
15:30 – 16:00 Coffee Break						
	PD 17 Page 86	PD 17 Page 86	PD 18 Page 88	PD 19 Page 90	WS 13 Page 92	WS 14 Page 94
16:00 – 18:30	Perspectives from the COVID-19 Pandemic International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)	Overflow PD 17	Climate Change and One Health German National Academy of Sciences Leopoldina InterAcademy Partnership The Lancet One Health Commission	Essential Surgical and Trauma Care AO Alliance Foundation Program in Global Surgery and Social Change of the Harvard Medical School	'Building Back Better' with Smart Investments in NCDs NCD Alliance Sanofi	Overcoming Cultural Barriers through Respect and Dialogue InterAcademy Partnership (IAP) MB Alliance

TUESDAY | OCTOBER 27, 2020

	SAAL 1 RUDOLF VIRCHOW	SAAL 6 EUROPE	SAAL 10 ASIA	SAAL 2 AMERICA	SAAL 4 AFRICA	SAAL 5 OCEANIA
	PD 20 Page 98	PD 20 Page 98	PD 21 Page 100	PD 22 Page 102	WS 15 Page 104	WS 16 Page 106
9:00 – 10:30	COVID 50/50: Women Leading in Crisis Women in Global Health	Overflow PD 20	Decade of Action: Accelerating Progress on the Health-Related SDGs at Country Level German Federal Ministry of Health (BMG) World Health Organization (WHO)	Access to Essential Medicines in LMICs Medicines Patent Pool (MPP)	Cardiovascular Health Max Delbrück Center for Molecular Medicine (MDC)	Developing Strategies for Fighting COVID-19 Around the World (Part 1) German Federal Ministry for Economic Cooperation and Development (BMZ)

10:30 – 11:00 Coffee Break

	PD 23 Page 108	PD 23 Page 108	PD 24 Page 110	PD 25 Page 112	WS 17 Page 114	WS 18 Page 116
11:00 – 12:30	GOARN 2020: Changing the Face of Outbreak Support Global Outbreak Alert and Response Network (GOARN) Robert Koch Institute (RKI) World Health Organization (WHO)	Overflow PD 23	Migrant and Refugee Health MB Alliance Sapienza University of Rome	Women's Health in the COVID-19 Era Charité – Universitäts-medicin Berlin MB Alliance	Fighting Falsified and Substandard Medicines during the COVID-19 Crisis Association of Research-based Pharmaceutical Companies (vfa) German Federal Ministry for Economic Affairs and Energy (BMWi)	Developing Strategies for Fighting COVID-19 Around the World (Part 2) German Federal Ministry for Economic Cooperation and Development (BMZ)

12:30 – 14:00 Lunch Break

	PD 26 Page 118	PD 26 Page 118				
13:00 – 13:30	BMJ Collection— Women's Health and Gender Inequalities	Overflow PD 26				
	KEY 05 Page 120	PD 27 Page 122			WS 19 Page 124	WS 20 Page 126
14:00 – 15:30	Partnership for the Goals German Federal Ministry of Health (BMG) World Health Organization (WHO)	Digital Health & AI for Pandemic Preparedness Global He@lth 2030 Innovation Task Force			A European Union in Health Charité – Universitäts-medicin Berlin MB Alliance	New Voices in Global Health Global Young Academy (GYA)

15:30 – 16:00 Coffee Break

	KEY 06 Page 128					
16:00 – 17:30	Accelerating the SDG 3 Global Action Plan for Health and Well-being German Federal Ministry of Health (BMG) World Health Organization (WHO)					

Welcome Messages 6

- High Patrons of the World Health Summit 6
- World Health Summit Presidents 12
- Charité – Universitätsmedizin Berlin 13

About the World Health Summit 14

About the M8 Alliance 15

Central Topics 2020 16

Program 19

- Sunday, October 25 19
- Monday, October 26 53
- Tuesday, October 27 97

General Information 131

- Good to Know 132
- City of Berlin 134
- World Health Summit Leadership 136
- M8 Alliance Leadership 140
- Speakers Index 143
- Institutions Index 146
- Partners 148
- World Health Summit Office 153
- Imprint 156

WELCOME MESSAGES

HIGH PATRONS OF THE WORLD HEALTH SUMMIT



Coronavirus has confronted us with a huge challenge on a global scale. The unprecedented magnitude of the health, humanitarian and economic effects requires an unprecedented measure of cooperation to deal with the pandemic. Numerous experts, engaged in an in-depth exchange of views on this extraordinary challenge at this year's World Health Summit, are making an enormous contribution towards this. For that I am deeply grateful and I would like to warmly welcome you to Berlin.

The German Government is doing everything in its power to ensure that a safe and effective vaccine can be made available as quickly as possible in Germany, in Europe and around the world. We have provided a substantial level of funding for this. This is not only enabling us to expand the re-

search, development and production capacities in Germany but also to support the Coalition for Epidemic Preparedness Innovations—an international coalition made up of public and private partners.

Together we must, above all, turn our attention to those countries which have been hit particularly severely by the pandemic—countries with a high population density, extreme poverty and overburdened health systems. People suffering from underlying health problems, hunger or malnutrition as well as those with no access to safe drinking water have a higher risk of becoming infected and seriously ill. Wherever they are in the world—we must not leave them to cope alone.

Germany would like to live up to its international responsibility by adopting a comprehensive and coherent approach. That is why we are cooperating with the WHO, the European Commission and other international partners, among other things to further the Access to COVID-19 Tools Accelerator. The aim of this multilateral platform is not only to develop vaccines but

also to ensure their fair distribution as well as that of suitable drugs and diagnostic tests. I will continue to call for the largest possible number of international partners to support this helpful initiative.

Coronavirus knows no borders. The necessary global response must therefore not fail due to national borders. The key to containing and overcoming the pandemic can only be found in international cooperation and coordination. That is why I am deeply grateful to you for contributing your expertise to the World Health Summit, exchanging findings and drawing up recommendations. I wish you all the best, and above all of course, that you stay healthy.

A handwritten signature in dark ink, which appears to read 'Angela Merkel'.

Angela Merkel

Chancellor of the
Federal Republic of Germany



The year 2020 will go down in the history of all nations as a memorable year due to the shock of the unprecedented Covid-19 pandemic that we have collectively faced. As the World Health Summit begins in Berlin and around the world via our screens, more than one million people have died, and the pandemic is still active.

In this new context, international forces have divided, concerted, and cooperated. The world-renowned World Health Summit gives us a great opportunity to bring together capable people of good will, in order to find solutions to this crisis.

I would like to thank my friend and outstanding leader Chancellor Angela Merkel, to offer once again her High Patronage, as well as Professor Ganten's dynamic organisation for allowing specialists

and the world's best experts to present their analyses, their knowledge and to discuss their opinions. I am delighted that this session gives us a particular opportunity to bring to light our European vision, at a time when Europe is strengthening its health agenda, under the German presidency of the European Union.

The World Health Summit has made us understand that the scientific world can help us make better decisions on global health. I call here for a global health policy that are based on the latest scientific knowledge, that can be shared and proved accurate by peer review.

We have been working—we nations, international organizations, foundations, and experts—to learn more about the COVID-19 pandemic. The World Health Organisation (WHO), as the leading organization in health, has played a key role, consolidating and providing epidemiological analysis for the world.

France has supported the WHO and is contributing, along with Germany, to multilateral reflections on strengthening and improving its

capacities to anticipate and react to crises. The WHO is the only world organization capable of carrying out this mission; it is crucial that we reinforce it for the future, as a new emerging virus might affect the human population. France has stepped up its support to WHO, and to the WHO Academy, which is essential to provide training resources worldwide, particularly in times of crisis.

The multilateral response to the Covid-19 crisis was unprecedented. In March, world leaders gave a mandate to WHO to coordinate the response, and within weeks the Access to Covid-19 tools accelerator (ACT-A) was launched. France, Germany, the European Union, as well as many other States and donors were at the heart of this initiative and endowed it with significant resources. ACT-A is a novel approach, led by a consortium of international health actors, WHO, the Global Fund to Fight AIDS, Tuberculosis and Malaria, the GAVI Vaccine Alliance, Unitaïd and the World Bank have pooled their resources to find practical solutions to provide the world with diagnostics, treatments and vac-

cines and to increase the capacity to distribute products worldwide. Much has been done and more is to come.

Once the vaccine is found, it will be a global public good. That means that it will have to be proved safe and efficient according to scientific and regulating authorities, accessible to all who need it, in all countries. It must be equitably distributed around the world on ethical principles, prioritising vulnerable populations and health workers.

France is also very keen to highlight the interaction between human, animal and planetary health. Science will provide us with clear ways. The Covid-19 crisis has been a revealing event and harbinger of a new world, as we have witnessed the direct effects of bio-

diversity on human health. Our generation needs to protect those who are ahead of us and those who follow us.

Together with our closest partners, such as Germany, France is keen to bring the “One Health” agenda to the fore, promoting further integration of sustainable development goals cross sectorial scientific knowledge.

This year, in which global health has been at the forefront of our priorities, has confirmed the analyses we have been making for a long time: the social determinants of disease are of great importance and women and vulnerable populations are the first and hardest hit.

As the global public health community, we must safeguard the

health of all people without leaving anyone behind. Women’s health will be an area for action supported by France in view the Generation Equality Forum in 2021.

I hope this 12th session of the World Health Summit year will be as thought provoking as the previous session and even more, considering the extraordinary challenges of the time.



Emmanuel Macron

President of the Republic of France



This twelfth edition of the World Health Summit is anything but business as usual. With all continents hit by COVID-19 in 2020, this World Health Summit is the first one since the World Health Organization has characterized this virus as a pandemic.

From all over the world, health experts and leaders are gathering this year again in Berlin to draw the lessons and consequences of this pandemic. There is so much to be learnt and shared.

First, this pandemic has reminded us that health truly is multidimensional: a new virus, which no one had heard of this time last year, created a butterfly effect of vast outreaching health challenges spanning the globe. It required the coming together of many scientists, researchers, and medical profes-

sionals amongst many others to work around the clock to understand the virus, its progression to cause disease, and to develop vaccines and therapeutics. But also to inform health policies and guidance for our citizens, economies and societies.

The EU invested €459 million in grants for 103 new research projects, and by the end of 2020, the EU will invest €1 billion into research and innovation to tackle COVID-19. We are investing heavily in research and innovation but also in our Vaccines Strategy to boost production capacity of companies who will supply vaccines for both EU and non-EU countries.

Second, we need to be collectively much better prepared for future health challenges. We do not want to experience again shortages of personal protective equipment, intensive care units overflowing, and healthcare professionals struggling to cope with the excessive demands. Global challenges associated with the climate, trade and health will continue to bring new and emerging global health challenges. The EU is ready to step up

and take more responsibility in the health sector.

The third lesson is that when viruses go global, we need immediate global action to bring global solutions. Some very positive strides are being made: we raised nearly €16 billion under the Coronavirus Global Response through a global call for action. No country in the world, no Union is large and strong enough to address these challenges on their own. This is why the position of the European Commission is clear: we want to promote multilateral cooperation and improve and reform the World Health Organization to make it ready to face the health challenges of the twenty-first century, for the benefit of everyone on every continent.

We have all felt the impact of this pandemic in some form, and we can and we are coming together to overcome this terrible disease. I wish each of you a healthy summit as well as an inspiring learning experience.

A handwritten signature in dark ink, which appears to read 'Ursula von der Leyen'.

Ursula von der Leyen
President of the European Commission



The COVID-19 pandemic has disrupted our world. The manner in which we conduct ourselves during this crisis, whether we learn lessons from it, and how we chose to build back better, is up to us.

Since the novel coronavirus took hold more than nine months ago, lives and livelihoods have been lost and economies and societies have been upended. The pandemic has exposed and exploited our political fault lines and inequalities, and the gaps in our health systems. The impacts go far beyond the suffering caused by the virus itself, with major disruptions to services for global hunger, immunization, noncommunicable diseases, family planning and more.

It has never been clearer that health is a political and economic choice. In the past 20 years, countries have invested heavily in preparing for terrorist attacks, but relatively little in preparing for the attack of a virus—which, as the pandemic has proven, can be far more deadly, disruptive, and costly.

Thanks to advances in biology, science and technology, we have been able to greatly accelerate the research and development for vaccines, diagnostics and therapeutics for COVID-19. No disease in history has benefited from such rapid research.

But the greatest challenge we face now is not scientific or technical. We face a test of our character. Can countries come together in solidarity to share the fruits of research? Or will misguided nationalism hobble our response?

In April, WHO, the European Commission and multiple other partners launched The Access to COVID-19 Tools Accelerator, to

catalyse the development and equitable distribution of vaccines, diagnostics and therapeutics.

Yet, even as we marshal our forces to bring this pandemic to an end, we must also work with equal urgency to strengthen our health systems and public health infrastructure so that the world is never again blindsided by a health emergency. A strong health system is a resilient health system.

The lessons so far are clear.

The first is that health is not a luxury item for those who can afford it; it is a necessity, a human right and the foundation of social, economic and political stability. The second is that there has never been a greater need for global cooperation and to confront a global threat. A coherent international response is key.

And the third is that the time to prepare for emergencies is before they occur. COVID-19 has demonstrated that the world was not

prepared. Even some of the most advanced societies and economies have been overwhelmed. While many countries put enormous resources into sophisticated medical care, too many also neglect their basic public health systems. We are paying the price for that now.

Investments in disease surveillance and monitoring, health promotion, water, sanitation and hygiene, educating and empowering communities and building a strong health workforce are essential for building resilient public health systems.

The absence of any one of these leaves communities vulnerable and undermines the timely response necessary to contain outbreaks.

Some countries are already showing the way. The German Chancellor, Angela Merkel, has announced that Germany will invest €4 billion by 2026 to strengthen its public health system.

Ultimately, the best defence against the impact of outbreaks

and other health emergencies is a strong health system, built on primary health care with an emphasis on promoting health and preventing disease.

That's why WHO's top three priorities are healthier populations, universal health coverage and health security.

This will not be the last pandemic or global health emergency we will face. When the next one comes, the world must be ready. Part of every country's commitment to build back better must therefore be to public health, as an investment in a healthier and safer future.

My best wishes for a productive and inspiring Summit.



Tedros Adhanom Ghebreyesus
Director-General of the
World Health Organization (WHO)

WELCOME MESSAGE

WORLD HEALTH SUMMIT PRESIDENTS



Charles Ibingira



Detlev Ganten

WELCOME TO THE WORLD HEALTH SUMMIT 2020

The spread of COVID-19 this year shows how essential the improvement of global health is and how crucial the strengthening of international and interdisciplinary cooperation remains.

A meeting like the World Health Summit with our strong partners, especially also the WHO, could not be more important in these days.

The COVID-19 epidemic has catapulted global health into the political focus. It has also reinforced the consistent message of the World Health Summit and our academic backbone, the M8 Alliance, that progress in global health is based on political choices and the application of strong policy-making instruments of governments and international institutions worldwide.

The World Health Summit brings together stakeholders from around the globe to engage in solutions. We consider strong and reliable governance—at global, national and local levels—essential for health and wellbeing. The world needs strong institutions to set norms and standards to be able to respond effectively to health deter-

minants, outbreaks and to protect and support the most vulnerable. Their work needs the support of decision makers at the highest level. We therefore strongly support the important role of the WHO.

Reflecting on these past months of living with the COVID-19 pandemic, we are hopeful that this global health crisis emphasizes the essential nature of international, multilateral cooperation and will lead to the strengthening of multinational structures and organizations. Because viruses, infectious diseases, or other health threats, know no borders.

The World Health Summit and the M8 Alliance provide an ever more important forum for science, industry, civil society and politics. We are excited to welcome so many diverse speakers from different organizations who contribute tremendously to advancing science and educating the public. An educated public is more important than ever in this unprecedented health crisis to understand the voice of science and to understand the necessary measures to curb the spread of COVID-19.

We look forward to your participation at the World Health Summit 2020—in Berlin or online. Please remain healthy and keep safe.

Charles Ibingira

International President 2020
World Health Summit

Principal, Makerere University
College of Health Sciences, Uganda

Detlev Ganten

Founding President
World Health Summit



Heyo Kroemer



Axel Radlach Pries

DEAR WORLD HEALTH SUMMIT PARTICIPANTS

2020 is a remarkable year, and we are all the more pleased to welcome you at this year's World Health Summit.

Charité – Universitätsmedizin Berlin looks back on a history of more than 300 years and, as the largest university hospital in Europe, it stands for excellent patient care and research, practice-oriented teaching and innovative developments. One of the most successful initiatives was the founding of the World Health Summit from within Charité, and now—12 years later—we proudly look at one of the world's largest health conferences, which brings together experts from more than 100 countries every year.

For the first time, the event will take place as an on-site event and digital conference, thus enabling the more than ever important exchange and cooperation between nations to improve global health. 2020 has been shaped both by the corona pandemic and activities and discussions on climate change. We live in times of uncertainty, false reports and hostility, but also in times of hope, commitment and networking. Let us take this opportunity to contribute to education and knowledge exchange, to strengthen prevention and health promotion, and to develop a variety of sustainability options.

As Charité, we are proud of the World Health Summit, the associated exchange and the work of the M8 Alliance—the academic backbone of the World Health Summit. We thank you for your interest, your work and your commitment. Let us work together to make the world a healthier place.

We wish you an interesting and exciting World Health Summit. Stay healthy.

Heyo Kroemer
Chief Executive Officer
Charité – Universitätsmedizin
Berlin

Axel Radlach Pries
Dean
Charité – Universitätsmedizin
Berlin

ABOUT THE WORLD HEALTH SUMMIT



SCIENCE – INNOVATION – POLICIES

The World Health Summit is one of the world's leading strategic forums for global health. Held annually in Berlin, it brings together leaders from politics, science and medicine, the private sector, and civil society to set the agenda for a healthier future. Speakers and participants from all over the world include:

- Leading scientists and medical professionals
- Ministers and civil servants
- High-ranking officials at international organizations
- CEOs from industry and civil society
- Young professionals and students

The mission of the World Health Summit is to improve health worldwide by:

- Bringing together all stakeholders
- Facilitating constructive exchange in an environment of academic freedom
- Finding answers to major health challenges
- Making global recommendations and setting health agendas

The World Health Summit was founded in 2009, on the occasion of the 300th anniversary of Charité.

www.worldhealthsummit.org





The “M8 Alliance of Academic Health Centers, Universities and National Academies” is the academic foundation of the World Health Summit. The International Presidency of the World Health Summit rotates annually among the members of the M8 Alliance. It is a growing network and currently consists of 28 members in 19 countries, including the InterAcademy Partnership, which represents the national academies of medicine and science in 130 countries.

All members are committed to improving global health and working with political and economic decision-

makers to develop science-based solutions to health challenges worldwide.

The M8 Alliance organizes annual Regional Meetings, regular Expert Meetings, and Summer Schools. As a result of each World Health Summit the M8 Alliance issues the M8 Declaration: recommendations for action to international policymakers.

The M8 Alliance was initiated by Charité – Universitätsmedizin Berlin in 2009 on the occasion of the first World Health Summit.



**Pandemic Preparedness in the Age of COVID-19:
Global Cooperation not Competition**

The COVID-19 pandemic has once again shown that we need everyone to get involved in a massive effort to keep the world safe. Researchers are working at high speed to understand new viruses, develop treatments and vaccines to curb pandemics and prevent future outbreaks. With COVID-19 new forms of collaboration have emerged for scientists around the world to share results much faster than during any previous outbreaks. With leadership by the World Health Organization (WHO), science has to take a collective and non-discriminative responsibility to support such a global governance.

**Strengthening the Role of the European Union
in Global Health**

In recent years, Germany has strengthened its commitment to global health, leveraging its G7 and G20 presidencies and lending support to multilateral and bilateral health partnerships. It has also become one of the strongest supporters of the World Health Organization and other international agencies. Germany has announced that global health will be a priority during its 2020 EU presidency, in cooperation with its triopartners Portugal and Slovenia. This presents a significant opportunity to help identify interventions in areas like development, health, research, environment, and trade that all EU members can implement to achieve SDG 3.

**Climate Change and Health:
Risks and Responses**

Unprecedented changes are occurring in natural systems that threaten to undermine progress in human health. Sustained population health requires the life-supporting “services” of natural systems. Populations of all animal species depend on supplies of food and water, low exposure to major infectious diseases, and a stable climate. Urgent action is needed to reduce the greenhouse gas emissions leading to rapid climate change and to address other environmental trends that pose increasing health risks.

**Partnership for the Goals:
United Nations’ 75th Anniversary**

Achieving the Sustainable Development Goals, our shared vision for the future, will require cooperation across borders, sectors, and generations. But just when we need collective action more than ever, support for global cooperation is flagging. In many countries, public trust in traditional institutions is in decline and relations between countries are under strain. Dialogue and action on global issues—nearly all of which directly and indirectly affect health—could not be more urgent. Through these conversations, the UN aims to build a global vision of 2045 (its centenary), increase understanding of the threats to that future, and support enhanced international cooperation to realize that vision.

Accelerating the SDG 3 Global Action Plan for Health and Well-Being

The Global Action Plan for Healthy Lives and Well-Being for All brings together 12 multilateral health, development, and humanitarian agencies to better support countries and accelerate progress towards health-related Sustainable Development Goals. Under the Global Action Plan, the agencies are better aligning their work to reduce inefficiencies and provide more streamlined support to countries and forums for international commitments to health, such as the UN High-Level Meeting on Universal Health Coverage and the Astana Conference on Primary Health Care. At the World Health Summit, representatives of the signatory agencies will present updates on the Action Plan, and its challenges and successes.

**Translational Research:
Advancing Innovative Treatments**

Translational research is part of a bidirectional process in which research findings are moved from the researcher's bench to the patient's bedside, but also back from clinical findings into mechanistic research. Development of new diagnostic and informatics methods has seen a trend towards more personalized therapeutic approaches. Information on individuals' genomic/transcriptomic profiles, in combination with lifestyle and environmental factors, are integrated to guide medical decisions in terms of prevention, diagnosis, and treatment of disease.

Digital Health & AI for Pandemic Preparedness

Following the first meeting of world leaders on universal health coverage (UHC) and launch of the Global Action Plan for Healthy Lives and Well-Being for All at the UN General Assembly in 2019, as well as the WHO Director-General 2020 "Global Strategy on Digital Health," the stakes for advancing a truly global market in digital health have taken on a new dimension. The next step is ensuring a transformative and multi-stakeholder ecosystem for the sustainability of innovations and growth of digital public goods, their economic viability, scale-up, and inclusivity.

PROGRAM

SUNDAY, OCTOBER 25

PD 01

Live | SAAL 1
RUDOLF VIRCHOW

Overflow | SAAL 6
EUROPE

11:00 – 12:30



PANEL DISCUSSION

COVID-19 DRIVING EFFECTIVENESS AND EFFICIENCY IN HEALTHCARE

HOST

Siemens Healthineers AG

Healthcare needs to become more accessible and affordable for patients. Digitalization and best practices from other sectors will facilitate this transformation. This transformation of Healthcare has been a topic before the COVID-19 pandemic. COVID-19 however has forced us to become more flexible and find new ways to deliver healthcare. The speed and flexibility of Healthcare providers, legislators, authorities and industry has been impressive and inspiring. It has shown us what can be achieved if there is imminent need and a common goal.

But Healthcare it is not only about speed and efficiency—we are touching human health and we are dealing with sensitive personal information. While taking the opportunities, we have to strike the right balance and protect the integrity of the individual. The worldwide pandemic has turned the focus of policy makers to healthcare topics in an unprecedented manner and has shown to every person that individual interests and the common interest have to be weighed against each other for the benefit of all.

CHAIR

Dagmar Mundani

Siemens Healthineers AG | Compliance and ECC | General Counsel
and Head of Healthcare Legal, Compliance and ECC |
Germany

SPEAKERS

Ricardo Baptista Leite

UNITE | Founder and President |
Portugal

Alena Buyx

TUM School of Medicine |
Professor of Ethics in Medicine
and Health Technologies |
Germany

Francesca Colombo

Organization for Economic Cooperation
and Development (OECD) |
Head of the Health Division |
France

Bart de Witte

HIPPO AI Foundation and
Health Academy | Founder |
Germany

Ulrich Dirnagl

Charité – Universitätsmedizin Berlin |
Department of Experimental Neurology |
Director of the Department |
Germany

Michael Neumaier

Heidelberg University |
Institute for Clinical Chemistry |
Director of the Institute |
Germany



Ricardo
Baptista Leite



Ulrich
Dirnagl



Alena
Buyx



Dagmar
Mundani



Francesca
Colombo



Michael
Neumaier



Bart
de Witte

PD 02

SAAL 10 | ASIA
11:00 – 12:30



PANEL DISCUSSION

DEVELOPING ANTIBIOTICS FOR CHILDREN TO ACHIEVE SDG 3

HOST

Global Antibiotic Research & Development Partnership (GARDP)

Sepsis, a complication of infection encompassing bloodstream infections, meningitis and pneumonia, is the third most common cause of death among newborns, accounting for 225,000 deaths globally every year. The World Health Organization has called for urgent action to accelerate the development of new antibiotics for bacterial infections, including sepsis, alongside expanded access to antibiotics for newborns and children, in order to facilitate achievement of Sustainable Development Goal 3: Health and Wellbeing for All.

Children and newborns are not small adults and their bodies may respond differently to drugs. It is critical to establish the correct dose and confirm safety and effectiveness of new and currently available treatments for children under 5. Although regulatory agencies require pharmaceutical companies to develop

plans to evaluate new antibiotics for use in children, these are often not started until after drugs are registered for use in adults. A recent study found that of 37 antibiotics being developed in adults, just two were being studied in children.

Addressing the challenge of developing new and expanded access to urgently needed antibiotics for children under 5 cannot be solved by one country, company or organization alone. It can only be addressed through a global and multi-sectorial approach. Partnerships between governments, industry, academia and civil society are needed to ensure plans are developed and resources are optimized to accelerate antibiotic research, development and access for children.

Within this session, the panel will discuss the unique challenges of antibiotic research focusing on children and newborns.

This will include the progress being made, and further action required to develop new treatments and ensure

expanded access to treatments for children and newborns to achieve SDG 3 and the Every Newborn Action Plan.

CHAIR

Claire Doole

Doole Communications | Coach, Trainer, Moderator | Switzerland

SPEAKERS

Nicholas Adomakoh

Sandoz | Global Medical Affairs
Lead for Anti-Infectives |
Germany

Manica Balasegaram

Global Antibiotic Research &
Development Partnership (GARDP) |
Director |
Switzerland

Alex Costa

UNICEF | Global HIV/AIDS Program |
HIV/AIDS Specialist

Elmar Nimmesgern

Global AMR R&D Hub |
Secretariat Lead |
Germany

Christina Obiero

KEMRI | Wellcome Trust |
Research Medical Officer |
Kenya

Dagmar Reitenbach

Federal Ministry of Health |
Head of Division Global Health |
Germany

Sithembiso Velaphi

Chris Hani Baragwanath Academic
Hospital | Associate Professor
University of the Witwatersrand
and Head of Paediatrics |
South Africa



Nicholas
Adomakoh



Elmar
Nimmesgern



Manica
Balasegaram



Christina
Obiero



Alex
Costa



Sithembiso
Velaphi



Claire
Doole

PD 03

SAAL 2 | AMERICA
11:00 – 12:30



PANEL DISCUSSION

ANTIMICROBIAL RESISTANCE

How to Solve the Issue of Shortages of Existing Antibiotics
and Preserve the Environment from Discharges

HOST

World Health Organization (WHO)

Past years have seen a growing attention towards antimicrobial resistance that led to a number of new initiatives in particular to foster the development of new antibacterial treatments. In parallel, another problem is surging and getting increasing public attention: the lack of supply of existing generic antibiotics. Many hospitals even in developed countries are facing difficulties in ensuring a steady supply of critical first line treatments, in particular injectable antibiotics preventing doctors from using the recommended antibiotics and increasing costs.

The problem has increased exponentially over the past years in many countries.

Current antibiotic producers in Europe keep closing manufacturing facilities for finished products and active pharmaceutical ingredients. Procurement practices that are driving prices down combined with fierce competition with companies from India and manufacturers in China and relatively high production standards and costs in Europe are some reasons behind this trend.

This session is going to shed light on the challenges and the risks and possible solutions to keep a steady supply of existing generic antibiotics and will link this issue to the conditions under which these products are produced.

CHAIR

Peter Beyer
World Health Organization (WHO) | Senior Advisor

SPEAKERS

Steve Brooks
AMR Industry Alliance | Advisor |
Switzerland

Dame Sally Davies
UK Government | Department of
Health and Social Care | Special Envoy
on Antimicrobial Resistance |
United Kingdom

Thomas Garms
Asklepios Kliniken GmbH | Pharmacist |
Germany

Joakim Larsson
University of Gothenburg |
Interdisciplinary Centre for Antibiotic
Resistance Research | Director |
Sweden

Céline Pulcini
Ministry for Solidarity and Health |
Antimicrobial Resistance
National Action Plan Coordinator |
France



Peter
Beyer



Joakim
Larsson



Steve
Brooks



Céline
Pulcini



Dame Sally
Davies

WS 01

SAAL 4 | AFRICA
11:00 – 12:30

HZI HELMHOLTZ
Centre for Infection Research

WORKSHOP

DIGITAL COVID-19 PANDEMIC RESPONSE MANAGEMENT

SORMAS for COVID-19 Response Across the Globe

HOST

Helmholtz Centre for Infection Research (HZI)

The COVID-19 pandemic has led to an exponential increase in demand and application of SORMAS for the digital integration of surveillance, laboratory diagnostics and contact person follow-up, isolation and quarantine measures. The digital and mobile SORMAS (Surveillance Outbreak Response Management and Analysis System) has not only experienced a rapid expansion geographically but also a technological boost with respect to global goods maturity, scalability and novel information technologies (www.sormas.org).

The aim of this session is to have front line health officers, coordinators, stakeholders and researchers from five different regions of the world share their experience in the development, deployment and application of SORMAS for the fight against COVID-19. Furthermore, the session aims to establish strategies for using the current momentum towards establishing a sustainable and comprehensive digital integration of surveillance and epidemic response beyond COVID-19. A major component of this will be to guide the transition from project mode toward a program mode of SORMAS and to develop sustainable open source business models compatible with global public health demands.

CHAIR

Gérard Krause

Helmholtz Centre for Infection Research (HZI) |
Department for Epidemiology | Head |
Germany

SPEAKERS

Franklin Asiedu-Bekoe

Ghana Health Service |
Disease Surveillance Department (DSD) |
Head of the Department |
Ghana

Carl Leitner

PATH | Digital Square |
Technical Director |
United States of America

Dagmar Starke

Academy for Public Health |
Deputy Director |
Germany

Lauro Vives

Gevity Consulting, Inc. |
International Development | Director |
Canada



Gérard
Krause



Dagmar
Starke



Carl
Leitner



Lauro
Vives

WS 02

SAAL 5 | OCEANIA
11:00 – 12:30

Johnson & Johnson

WORKSHOP

INNOVATIONS TO IMPROVE PANDEMIC PREPAREDNESS

How to Develop the Right Tools, at the Right Time

HOST

Johnson & Johnson

Diagnostics, vaccines and treatments are critical tools to monitor and halt an epidemic, in addition to adequate production capabilities and equitable access and delivery of these tools. When the viral sequence of COVID-19 became available, scientists from both the private sector and academia immediately began the search for vaccines and treatments, mobilizing resources and forming partnerships to spur innovation. Governments around the world have announced

research funding to combat this novel pathogen. What are the learnings from the scientific response to COVID-19? How can we strengthen cross-sector partnerships for innovation against emerging health security threats? How to distribute treatments and vaccines? What mechanisms should be in place to accelerate the development new tools and technologies to protect global health security?

CHAIR

Sabine Campe
Open Consultants | Managing Director | Germany

SPEAKERS

Catharina Boehme
Foundation for Innovative
New Diagnostics (FIND) | CEO |
Switzerland

Jayasree K. Iyer
Access to Medicine Foundation |
Executive Director |
The Netherlands

Paul Stoffels
Johnson & Johnson |
Vice Chair of the Executive Committee
and Chief Scientific Officer |
United States of America

Veronika von Messling
Federal Ministry of Education
and Research (BMBF) |
Life Sciences Division | Director-General |
Germany

Sir Andrew Witty
World Health Organization Special Envoy
to the ACT-Accelerator



Catharina
Boehme



Paul
Stoffels



Sabine
Campe



Veronika
von Messling



Jayasree K.
Iyer



Sir Andrew
Witty

PD 04

Live | SAAL 1
RUDOLF VIRCHOW

Overflow | SAAL 6
EUROPE

14:00 – 15:30

M8Alliance
Academic Health Centers, Universities and National Academies

**THE GRADUATE
INSTITUTE
GENEVA**
—
INSTITUT DE HAUTES
ÉTUDES INTERNATIONALES
ET DU DÉVELOPPEMENT
GRADUATE INSTITUTE
OF INTERNATIONAL AND
DEVELOPMENT STUDIES

PANEL DISCUSSION

MULTILATERAL PUBLIC HEALTH PARTNERSHIPS DURING THE COVID-19 CRISIS

HOSTS

M8 Alliance

The Graduate Institute of International and Development Studies

Multilateral cooperation is central in a pandemic. As the experiences in the COVID-19 pandemic show public health institutions play a central role in both preparedness and response at the national level and through their international cooperation. Over the last decade new centers for disease control have been established and existing centers have been strengthened, including at regional

level. In many cases these reforms have followed on major disease outbreaks: SARS, Ebola and now COVID-19. This session will discuss the experiences gained by centers of disease control in China, Africa, the European Union, Germany and France—and how they have strengthened their cooperation to support global health and what still remains to be done.

CHAIR

Ilona Kickbusch

The Graduate Institute of International and Development Studies |
Global Health Center | Chair of the International Advisory Board |
Switzerland

SPEAKERS

Andrea Ammon

European Centre for Disease Prevention
and Control (ECDC) | Director |
Sweden

George F. Gao

Chinese Center for Disease Control
and Prevention | Director |
China

John Nkengasong

Africa Centres for Disease Control
and Prevention | Director |
Ethiopia

Stéphanie Seydoux

Ministry for Europe and Foreign Affairs
(MEAE) | Ambassador for Global Health |
France

Lothar H. Wieler

Robert Koch Institute (RKI) | President |
Germany



Andrea
Ammon



John
Nkengasong



George F.
Gao



Stéphanie
Seydoux



Ilona
Kickbusch



Lothar H.
Wieler

PD 05

SAAL 10 | ASIA
14:00 – 15:30



UNIVERSITY OF
EASTERN FINLAND

PANEL DISCUSSION

NURSING IN THE TIME OF COVID-19

HOST

University of Eastern Finland

The World Health Organization designates 2020 as the International Year of the Nurse and Midwife. Nurses are considered the backbone of the healthcare system comprising of at least 60% of the total global health workforce. They are essential health workforce in the attainment of the Universal Health Coverage (UHC) and Sustainable Development Goals (SDGs). As the world succumbs from the pandemic case of COVID-19, nurses fulfill their duties in saving lives but remain undervalued in many countries.

For the past decade, the role of the nursing profession has long been proven vital in the global health and pandemic crisis such as Zika virus, Ebola virus and the most recent Corona virus. They are the frontline healthcare workers delivering essential care based on the available resources with the highest form of work

morale and ethics to the oppressed, depressed, exploited, and deprived vulnerable groups of the society. During pandemic times, nurses are involved in planning, organizing, implementing, and evaluating the effectiveness of the healthcare services using existing evidence-based practice.

Despite the evident role of nurses in the social and healthcare system, their visibility in the decision and policy-making process is limited and are not given the maximum potential to utilize their skills and competencies.

What are the factors hindering the advancement of nurses' role during pandemic times? How can member states of the World Health Organization commit to promoting and protecting the interests of nurses' welfare and health in a sustainable manner?

CHAIR

Floro Cubelo
Filipino Nurses Association in the Nordic Region | President | Finland

SPEAKERS

Jim Campbell
World Health Organization (WHO) |
Director of Health
Workforce Department

Elizabeth Iro
World Health Organization (WHO) |
Chief Nursing Officer

Annette Kennedy
International Council of Nurses (ICN) |
President |
Switzerland

Dame Donna Kinnair
Royal College of Nursing |
CEO and General Secretary |
United Kingdom

Katri Vehviläinen-Julkunen
University of Eastern Finland |
Faculty of Health Sciences | Chair |
Finland



Jim
Campbell



Annette
Kennedy



Floro
Cubelo



Dame Donna
Kinnair



Elizabeth
Iro



Katri
Vehviläinen-
Julkunen

PD 06

SAAL 2 | AMERICA
14:00 – 15:30

foundation
BOTNAR

PANEL DISCUSSION

A CALL TO ACTION FOR HEALTH DATA GOVERNANCE

HOST

Fondation Botnar

The convergence of big health data—from diverse data types and a broad range of personal, clinical, and environmental sources—with massive advances in information technology (IT) and artificial intelligence (AI) offers unprecedented opportunities for individual and public health. The comprehensive capturing and computational analysis of massive amounts of health-relevant data allows for innovative applications in disease prevention, diagnostics, treatment, but also for more efficient resource allocation, remote training or pre-basic care, to name just a few possibilities. Ultimately, “frontier technologies” have the potential to radically transform the way health-care is practiced—not only in affluent countries of the global north, but also in low-and middle-income countries.

Fast-moving technological developments and the growing aspirations—by service providers, donors, tech companies, health authorities, patients, consumers and many others—to field these technologies on a wide scale, however, lead to mounting concerns over data protection, privacy, and ownership. Yet, the majority of WHO Member States still lack robust national data governance and digital health frameworks, which could ensure that the new technologies deliver sustained health benefits while protecting informational rights. Investigating how data sharing and use for research, commercial and public health purposes can be aligned with calls for data protection, privacy, and informational self-determination, the panel discusses possible contours of a global health data governance instrument.

CHAIR

Stefan Germann
Fondation Botnar | CEO | Switzerland

SPEAKERS

Lawrence O. Gostin
Georgetown University |
O'Neill Institute for National and Global
Health Law | Director |
United States of America

Bernardo Mariano Jr.
World Health Organization (WHO) |
Department of Digital Health and
Innovation | Director of the Department
and the Chief Information Officer

Bernd Montag
Siemens Healthineers AG |
President and CEO |
Germany

Päivi Sillanaukee
Ministry of Foreign Affairs |
Ambassador for Health and Wellbeing |
Finland

Effy Vayena
ETH Zurich | Professor of Bioethics,
Health Ethics and Policy Lab |
Switzerland



Stefan
Germann



Bernd
Montag



Lawrence O.
Gostin



Päivi
Sillanaukee



Bernardo
Mariano Jr.



Effy
Vayena

WS 03

SAAL 4 | AFRICA

14:00 – 15:30



WORKSHOP

UNIVERSAL HEALTH COVERAGE

New Choices for Best Practices

HOST

Robert Bosch Foundation

'Universal Health Coverage' is one aim of Sustainable Development Goal 3 'Good health for all'. This highly ambitious aim brings about a number of challenges that were particularly laid open in the light of the corona-crisis: accessibility of health care facilities, quality of care provision, preventive versus curative measures of care, and health competence and literacy. We understand that health is not only dependent on effective medicine but essentially on overall health orientation in our health care structures with public

health, health promotion, and prevention building their basic fundament. Sustainable health care structures will also adapt to regional needs to (re-)act appropriately to geographical and social differences. Reliance on evidence about regional and population needs, on monitoring health (care) status, their progress and successful activities is vital. Social solidarity and a robust connection to civil society is here inevitable. A good level of health literacy of decision makers and population will fuel steady improvement.

CHAIR

Bernadette Klapper
Robert Bosch Foundation | Senior Vice President Health Division | Germany

SPEAKERS

Lakshmi Narasimhan Balaji
UNICEF | Health Systems
Strengthening Unit | Head

Marie-Paule Kieny
Inserm | Director of Research |
France

Tolullah Oni
University of Cambridge |
Senior Research Medical Officer |
United Kingdom

Mujaheed Shaikh
Hertie School |
Professor of Health Governance |
Germany

Kristin Sørensen
Global Health Literacy Academy |
Founding Director |
Denmark



Lakshmi Narasimhan Balaji



Tolullah Oni



Marie-Paule Kieny



Mujaheed Shaikh



Bernadette Klapper



Kristin Sørensen

WS 04

SAAL 5 | OCEANIA
CET: 14:00 – 15:30



WORKSHOP

CHANGES IN HEALTH RESEARCH DURING AND AFTER THE COVID-19 ERA

HOSTS

Berlin Institute of Health (BIH)

Charité – Universitätsmedizin Berlin

QUEST Center

As an unprecedented global health emergency, COVID-19 has also caused substantial change in the research process: health research fighting COVID-19 is faster, more open, and more collaborative than usual. It has both profited from and further accelerated pre-existing practices like preprint publishing and data sharing, and has expedited ethics-review and marketing approval. These changes elicit wide discussions, and have been both hailed and criticized. However, most controversies regarding openness, secondary-use of routine health data, translational success, re-purposing, and regulatory frameworks were apparent already before the pandemic, providing a backdrop to these discussions.

Other COVID-19 related issues are relatively new such as the allocation of scarce research resources and the negative impact on non-COVID-19 research. The rapid changes of current biomedical research thus go beyond the quality and ethics of COVID-19 research specifically, and lead to questions on future developments of research as a whole: What can we learn from these changes? Will they be lasting? Why should global research on other deadly diseases such as tuberculosis, malaria, cancer, or dementia be less open and less collaborative? And how are we to shape these changes to advance the global health research system?

The speakers are all at the forefront of changes precipitated by COVID-19 and represent different steps of the research process, from assessment and approval through conduct and publishing to the

ultimate translation of research findings. They will contribute their views on the pandemic's long-term impacts: whether health research will and should change, and if so, how.

CHAIRS

Ulrich Dirnagl

Berlin Institute of Health (BIH) |
QUEST Center | Founding Director |
Germany

Daniel Strech

Berlin Institute of Health (BIH) |
QUEST Center | Deputy Director |
Germany

SPEAKERS

Christopher Baum

Berlin Institute of Health (BIH) | CEO |
Germany

Theodora Bloom

The BMJ | Executive Editor |
United Kingdom

Ben Goldacre

University of Oxford |
Nuffield Department of Population Health |
Senior Clinical Research Fellow at the
Centre for Evidence-Based Medicine |
United Kingdom

Andreas Alois Reis

World Health Organization (WHO) |
Senior Ethics Officer



Christopher
Baum



Ben
Goldacre



Theodora
Bloom



Andreas Alois
Reis



Ulrich
Dirnagl



Daniel
Strech

PD 07

Live | SAAL 1
RUDOLF VIRCHOW
Overflow | SAAL 6
EUROPE
16:00 – 17:30



PANEL DISCUSSION

A FAST EUROPEAN RESPONSE TO PANDEMICS USING DATA AND JOINT INVESTMENTS IN HEALTH

HOST

Sanofi

Europe has spent 2020 dealing with the COVID-19 pandemic, which has caused unprecedented health and economic impact across countries.

It may be too early to analyze and learn every lesson from this experience, however it is clear that responses to future pandemics will require closer cooperation between countries and new models of public-private partnership to introduce innovation in health products, data and healthcare systems.

This session, organized in two panels, will focus on the development of such cooperation.

Panel 1 will look at the role data has played in predicting, tracing and containing infections. It will mostly focus on what may be possible in the future if proper privacy protections can be assured and if countries collaborate to use the predictive power of big data and new techniques to

assess rapidly the effectiveness of both social and biomedical interventions. A discussion will start on how these new partnerships might be funded.

Panel 2 will focus on how that funding may underpin new joint approaches to EU health security and crisis preparedness, including rapid deployment of emergency care capacity and new health technologies. It also involves development of flexible, state-of-the art, digitalized facilities for production of vaccines and medicines, which would ultimately support EU competitiveness and resilience. It will be important to have continued evolution of sharing of skills and knowledge between agencies and greater regulatory flexibility based upon that interconnectedness.

The session will maximize participation through electronic systems to poll, prioritize topics and collect the compelling questions from the audience.

CHAIR

Mark Chataway
Hydorus | Managing Director | United Kingdom

SPEAKERS

Olivier Véran
Ministry of Social Affairs and Health |
Minister of Solidarity and Health |
France

Andrea Ammon
European Centre for Disease Prevention
and Control (ECDC) | Director |
Sweden

Olivier Charmeil
Sanofi | General Medicines |
Executive Vice President |
France

Jürgen Müller
SAP SE | Chief Technology Officer (CTO)
and Member of the Executive Board |
Germany

Lothar H. Wieler
Robert Koch Institute (RKI) | President |
Germany



Olivier
Véran



Mark
Chataway



Andrea
Ammon



Jürgen
Müller



Olivier
Charmeil



Lothar H.
Wieler

PD 08

SAAL 10 | ASIA
16:00 – 17:30



MAX-PLANCK-GESELLSCHAFT

PANEL DISCUSSION

BRINGING THE COVID-19 EPIDEMIC UNDER CONTROL

The Need for Research & Innovation

HOSTS

Charité – Universitätsmedizin Berlin

Max Planck Institute for Infection Biology

COVID-19 caused by SARS-CoV-2 has changed the world. It is obvious that it can only be brought under control by breakthroughs in research & innovation. These include, first of all, the 3 canonical pillars of medical intervention, namely diagnosis, therapy and vaccination. In addition, host-directed therapies and biomarkers are needed.

Diagnosis of SARS-CoV-2 infection based on RNA measurements is well established and broadly used. Diagnosis of immunity to SARS-CoV-2 based on serum antibody measurements is in progress and validated tests will become available soon.

Efficacious treatment by antiviral compounds is progressing and emphasis has been given to drugs that had been developed previously for other viral infections.

Global access to efficacious intervention measures, notably vaccines, will face the issue of (i) supply of large numbers (hundreds of millions) of doses and (ii) affordable price. Hence, discussions need to be initiated as soon as possible on issues such as rapid large-scale vaccine production and affordable pricing (e.g. dual-price concepts for high vs. low income countries).

CHAIR

Stefan H.E. Kaufmann
Max Planck Institute for Infection Biology | Director Emeritus | Germany

SPEAKERS

Ruxandra Draghia-Akli
Janssen Pharmaceutical Companies
of Johnson & Johnson |
Global Public Health | Global R&D Head |
United Kingdom

Victor J. Dzau
National Academy of Medicine |
President |
United States of America

Richard Hatchett
Coalition for Epidemic Preparedness
Innovations (CEPI) | CEO |
Norway

Depei Liu
Chinese Academy of Engineering (CAE) |
Former Vice President, President IAP |
China

Trevor Mundel
Bill & Melinda Gates Foundation |
President of Global Health |
United States of America

Soumya Swaminathan
World Health Organization (WHO) |
Chief Scientist



Ruxandra
Draghia-Akli



Depei
Liu



Victor J.
Dzau



Trevor
Mundel



Richard
Hatchett



Soumya
Swaminathan



Stefan H.E.
Kaufmann

PD 09

SAAL 2 | AMERICA
16:00 – 17:30



PANEL DISCUSSION

STRONG PARTNERSHIPS AS A DETERMINANT OF HEALTH

Bridging the Public, Private, and Political Powers
to Accelerate the Attainment of the 2030 SDGs

HOSTS

GHA – German Health Alliance

UNAIDS

UNITE

One thing the sustainable development agenda has projected to the globe is the interdependency among the goals. On the road to reach the 2030 SDGs, it becomes clear that urgent commitments are needed to accelerate the attainment of health-related targets and SDG 3 (Ensure healthy lives and promote well-being for all at all ages). With the current health landscape, where infectious diseases account for near 4.3 million deaths (1.7 million female and 2.7 million male), a common agenda setting between the public and private sectors, that is leveraged by political powers and influences, is the determinant to achieve the 95-95-95 HIV/AIDS goals, reduce viral hepatitis infections to 900,000, reduce malaria case incidence by 90%, reduce mortality rate by tuberculosis by 90%, reduce the

number of people requiring interventions against neglected tropical diseases by 90%, among others (UNITE, 2019).

Evidence shows that to progress globally in achieving these goals will demand a paradigm shift, with new ways of doing partnerships and securing commitments at local, national and global levels (Bekker et al., 2019). The SDG 17 (Partnerships for the Goals) acknowledges that successful attainment of the sustainable development agenda requires effective partnerships to unlock the transformative power of trillions of dollars of private resources to deliver on sustainable development objectives (United Nations, 2015).

Considering this, UNITE – The Global Parliamentarians Network to End Infec-

tious Diseases, steps forward to place the role of partnerships for effective accomplishment of the 2030 SDGs on the global health agenda. It does so in partnership with the GHA – German Health Alliance, and the UNAIDS–Joint

United Nations Program on HIV/AIDS to promote a discussion and generate key recommendations on how to strengthen sustainable partnerships that are backed by political will to attain the effective achievement of health-related SDGs.

CHAIR

Ricardo Baptista Leite

UNITE | Founder and President | Portugal

SPEAKERS

Hila Azadzoy

Ada Health GmbH | Managing Director of Global Health Initiatives | Germany

Winnie Byanyima

Joint United Nations Programme on HIV and AIDS (UNAIDS) | Executive Director

Roland Göhde

GHA – German Health Alliance | Chairman of the Board | Germany

Hon. Given Katuta

Inter-Parliamentary Union (IPU) | Advisory Group on Health | Member of Parliament and Head of Group | Zambia

Hendrik Streeck

University Bonn | Institute of Virology and HIV Research | Director of the Institute | Germany

Andrew Ullmann

German Bundestag | Member of Parliament | Germany



Hila
Azadzoy



Hon. Given
Katuta



Ricardo
Baptista Leite



Hendrik
Streeck



Winnie
Byanyima



Andrew
Ullmann



Roland
Göhde

WS 05

SAAL 4 | AFRICA
16:00 – 17:30



WORKSHOP

RECOUPLING SOCIETAL WEALTH AND INDIVIDUAL HEALTH

From Efficiency to Resilience

HOST

Global Solutions Initiative

The COVID-19 pandemic was a stark reminder that health care systems in many countries lack the resources and resilience to cope with unexpected shocks. Beyond the current crisis, there is also stark differences between (wealthy) countries' capability to provide their citizens with the best health care possible. One primary reason is the strong focus in recent years and decades on making national health care more efficient, instead of focusing on resilience

and human wellbeing—(individual) health has thus been decoupled from (societal) wealth in many countries.

Focusing on the G20 as the largest economies and some of the world's wealthiest societies; this panel takes stock of the performance of national health systems in the COVID-19 pandemic and beyond and asks for ways to recouple health and wealth as part of a more human-centered development model.

CHAIR

Dennis J. Snower

Global Solutions Initiative | President | Germany

SPEAKERS

Francesca Colombo

Organization for Economic Cooperation and Development (OECD) | Head of the Health Division | France

Detlev Ganten

World Health Summit | President | Germany

Benoît Miribel

French Foundation Center (CFF) | Chairman of the French Foundations Center (CFF) and Secretary General of the foundation One Sustainable Health for All | France

Agnés Soucat

World Health Organization (WHO) | Director for Health Systems, Governance and Financing

Dana Vorisek

World Bank | Development Economics Prospects Group | Senior Economist | United States of America



Francesca Colombo



Dennis J. Snower



Detlev Ganten



Agnés Soucat



Benoît Miribel



Dana Vorisek

WS 06

SAAL 5 | OCEANIA
16:00 – 17:30



WORKSHOP

TRANSLATION IN THE TIMES OF COVID-19

HOST

Berlin Institute of Health (BIH)

Translational research is part of a bidirectional process in which research findings are moved from the researcher's bench to the patient's bedside, but also back from clinical findings into mechanistic research. Development of new diagnostic and informatics methods has seen a trend

towards more personalized therapeutic approaches. Information on individuals' genomic/transcriptomic profiles, in combination with lifestyle and environmental factors, are integrated to guide medical decisions in terms of prevention, diagnosis, and treatment of disease.

CHAIR

Christof von Kalle

Berlin Institute of Health (BIH) |
 BIH-Chair for Clinical Translational Sciences
 and Director of the Clinical Study Center |
 Germany

SPEAKERS

Catharina Boehme

Foundation for Innovative
 New Diagnostics (FIND) | CEO |
 Switzerland

Patrice Debré

Académie Nationale de Médecine |
 President of the International
 Relations Committee |
 France

Ralf Heyder

Charité – Universitätsmedizin Berlin |
 Head of Administrative Office
 for External Networking and
 Strategic Partnerships |
 Germany

Jochen Rupp

Bosch Healthcare Solutions |
 Head of Product Management Vivalytic |
 Germany

Peter H. Seeberger

Max Planck Institute of Colloids
 and Interfaces | Director |
 Germany



Catharina
Boehme



Jochen
Rupp



Patrice
Debré



Peter H.
Seeberger



Ralf
Heyder



Christof
von Kalle

KEY 01

SAAL 1
RUDOLF VIRCHOW
18:00 – 19:30



WORLD
HEALTH
SUMMIT

KEYNOTE

OPENING CEREMONY

HOSTS


M8 Alliance
World Health Summit

CHAIRS

- Detlev Ganten**
World Health Summit |
President |
Germany
- Charles Ibingira**
Makerere University |
University College of Health
Sciences | Principal |
Uganda

SPEAKERS

- Frank-Walter Steinmeier**
Federal President |
Germany
- Paul Hudson**
Sanofi | CEO |
France
- Ursula von der Leyen**
European Commission |
President
- Winnie Byanyima**
Joint United Nations Programme
on HIV and AIDS (UNAIDS) |
Executive Director
- António Guterres**
United Nations |
Secretary-General
- Nanette Cocero**
Pfizer Inc. | Global President
of Pfizer Vaccines |
United States of America
- Tedros Adhanom Ghebreyesus**
World Health Organization
(WHO) | Director-General



PROGRAM

MONDAY, OCTOBER 26

KEY 02

SAAL 1
RUDOLF VIRCHOW
9:00 – 10:30



KEYNOTE

ACHIEVING HEALTH FOR ALL THROUGH DIGITAL COLLABORATION

HOST

World Health Organization (WHO)

Digital technologies are revolutionizing healthcare and provide unprecedented opportunities to improve health and wellbeing worldwide, transform economies, and stimulate growth. For the first time in history, we have new tools to solve health system problems and create an equitable global health future.

If we are to realize the benefits of digital transformation in health care, it will take a global collaboration among Governments, Development Partners and Donors, the Private Sector, Civil Societies, Academics, and NGOs.

The purpose of this event is to engage the multi-stakeholder digital community to contribute to the prioritization, adoption and acceleration of digital health technologies and create a strong and sustainable partnership model for digital health as we encourage key stakeholders to invest in the global digital health ecosystem.

Please find the draft agenda here:
<https://www.who.int/docs/default-source/digital-health-documents/whs-who-event-draft-agenda.pdf>

MODERATOR

Amandeep Singh Gill
Project Director, International Digital Health & AI Research Collaborative (I-DAIR) | Switzerland

SPEAKERS

Tedros Adhanom Ghebreyesus
World Health Organization (WHO) | Director-General

Stella Kyriakides
European Commission | Commissioner for Health and Food Safety | Belgium

Soumya Swaminathan
World Health Organization (WHO) | Chief Scientist

Dame Sally Davies
UK Government | Department of Health and Social Care | Special Envoy on Antimicrobial Resistance | United Kingdom

Bernardo Mariano Jr.
World Health Organization (WHO) | Department of Digital Health and Innovation | Director of the Department and the Chief Information Officer

Aishath Samiya
Permanent Secretary | Ministry of Health | Maldives

Rajiv Shah
Rockefeller Foundation | President | United States of America

Miriam K. Were
The Champions for an AIDS-Free Generation in Africa | Deputy Chair | Botswana



Tedros Adhanom Ghebreyesus

Bernardo Mariano Jr.



Stella Kyriakides

Rajiv Shah



Soumya Swaminathan

Miriam K. Were



Dame Sally Davies

PD 10

SAAL 6 | EUROPE

9:00 – 10:30



PANEL DISCUSSION

NATIONAL RESPONSES
TO COVID-19

HOSTS

M8 Alliance

Tehran University of Medical Sciences (TUMS)

The George Washington University, Milken Institute School of Public Health

COVID-19 has affected all parts of the world as a global pandemic, affecting more people than recent epidemics. Yet nation states have responded differently, at variable time frames and with a diversity of political and public health actions. Scientists, experts, health professionals and researchers have been a part of these responses, and have also studied these action to try and define their motivations

and impact. To some this diversity of responses is surprising given the common experience of COVID-19; while to others this is a sign of variations in the political and contextual factors that affect decision making.

This session will discuss experiences from several parts of the world around the following key questions below.

CHAIRS

Adnan A. Hyder
The George Washington University |
Milken Institute School of Public Health |
Senior Associate Dean for Research
and Professor of Global Health |
United States of America

Amirhossein Takian
Tehran University of Medical Sciences
(TUMS) | Department of
Global Health & Public Policy |
Chair of Department and Vice Dean |
Iran

SPEAKERS

Chang-Chuan Chan
National Taiwan University |
Associate Dean |
Taiwan

Margaret Chan
Boao Forum For Asia | President

Martin Fitchet
Johnson & Johnson |
Head of Global Public Health |
United States of America

Joanna Nurse
InterAction Council | Strategic Advisor |
United Kingdom



Chang-Chuan
Chan

Adnan A.
Hyder



Margaret
Chan

Joanna
Nurse



Martin
Fitchet

Amirhossein
Takian

PD 11

SAAL 10 | ASIA
9:00 – 10:30



PANEL DISCUSSION

CLIMATE CHANGE AND HEALTH

Risks and Responses

HOSTS

London School of Hygiene & Tropical Medicine (LSHTM)

M8 Alliance

Our increasing understanding of climate change is transforming how we view the boundaries and determinants of human health. While our personal health may seem to relate mostly to prudent behavior, heredity, occupation, local environmental exposures, and health-care access, sustained population health requires the life-supporting “services” of natural systems. Populations of all animal species

depend on supplies of food and water, low exposure to major infectious diseases, and a stable climate. Unprecedented changes are occurring in natural systems that threaten to undermine progress in human health. Urgent action is needed to reduce the greenhouse gas emissions leading to rapid climate change and to address other environmental trends that pose increasing risks to human health.

CHAIR

Sabine Gabrysch
Charité – Universitätsmedizin Berlin |
Professor for Climate Change and Health |
Germany

Sir Andrew Haines
London School of Hygiene and Tropical
Medicine (LSHTM) | Professor of Environ-
mental Change and Public Health |
United Kingdom

SPEAKERS

Niels Annen
Federal Foreign Office |
Minister of State |
Germany

Rachel Huxley
C40 Cities Climate Leadership Group |
Knowledge and Learning |
Director |
United Kingdom

Jeni Miller
The Global Climate and Health Alliance |
Executive Director |
United States of America

Carlos A. Nobre
University of São Paulo |
Institute of Advanced Studies |
Senior Scientist |
Brazil



Niels
Annen



Rachel
Huxley



Sabine
Gabrysch



Jeni
Miller



Andrew
Haines



Carlos A.
Nobre

PD 12

SAAL 2 | AMERICA
9:00 – 10:30



PANEL DISCUSSION

ACCESS TO SUSTAINABLE NCD TREATMENT & CARE

HOSTS

Boehringer Ingelheim Pharma GmbH & Co. KG

The Defeat-NCD Partnership

More than half of all countries will fail to meet SDG target 3.4 by 2030. By all measures, the reduction by one-third of premature mortality due to non-communicable diseases (NCDs), can and should be achieved through prevention and treatment.

The political will and leadership is there, and in many cases a coherent NCD strategy is in place. But although their role is vital, these strategies need to be translated into costed action plans that bring together public and private actors to work alongside governments. Every part of society must take responsibility to bridge the trillion-dollar funding gap and find creative ways to bring about better health outcomes for NCDs.

This panel discussion will bring ministers at the forefront of tackling NCDs in Rwanda and Myanmar together with

experts and leaders from Governments, United Nations, World Health Organization, African Union, Association of South-east Asian Nations, regional development banks, and the private sector to reflect on how progress can be made towards this ambitious goal, offering different perspectives not just on the importance of a robust action plan, but on what it takes to implement such ambitious plans.

In light of this, the discussion will focus on tangible ways in which leadership, political will, and strong partnerships between the public and private sector actors can improve patient care (in particular reflecting the importance of partnerships in helping NCD patients during emergencies like COVID-19), strengthen health systems, and create access to financing through cost reduction and unlocking new funding streams.

MODERATOR

Juliette Foster
Magnus Communications | Founder and Managing Director | United Kingdom

SPEAKERS

Bente Mikkelsen
World Health Organization (WHO) |
Division of Noncommunicable Diseases
and Promoting Health through the
Life-course | Director

H.E. Amira Elfadil Mohammed Elfadil
African Union Commission |
Commissioner for Social Affairs |
Ethiopia

Hubertus von Baumbach
Boehringer Ingelheim Pharma GmbH
& Co. KG | Chairman of the Board
of Managing Directors |
Germany

H.E. Myint Htwe
Ministry of Health and Sports |
Minister of Health and Sports |
Myanmar

H.E. Daniel Ngamije
Ministry of Health |
Minister of Health |
Rwanda

Mukul Bhola
The Defeat-NCD Partnership | CEO |
Switzerland



Mukul Bhola H.E. Myint Htwe



H.E. Amira Elfadil Mohammed Elfadil Bente Mikkelsen



Juliette Foster H.E. Daniel Ngamije

WS 07

SAAL 4 | AFRICA
9:00 – 10:30



Federal Ministry
of Education
and Research

WORKSHOP

MULTI STAKEHOLDER COLLABORATION IN GLOBAL HEALTH RESEARCH

Science Meets Implementation

HOST

German Federal Ministry of Education and Research (BMBF)

The session will explore the relationships and intersections of development cooperation and academic research in global health. How can political, financial and human resources investments in humanitarian development cooperation be sensibly linked to academic research? What kind of coordination mechanisms are needed to overcome fragmentation between or even within sectors

(e.g. different Ministries and Departments) and improve the coherence, efficiency and capacity for action of donor countries? What kind of programs and incentives are needed to ensure that development cooperation programs are evidence based and that academic cooperation's have a positive impact on social and economic development in the partner countries?

CHAIRS**Walter Bruchhausen**

University Hospital Bonn |
Section Lead Global Health,
Social and Cultural Aspects |
Professor |
Germany

Johanna Hanefeld

London School of Hygiene
and Tropical Medicine (LSHTM) |
Lead LSHTM Berlin and Associate
Professor Health Policy and Systems |
Germany

SPEAKERS**Achim Hörauf**

University Hospital Bonn |
Institute of Medical Microbiology,
Immunology and Parasitology |
Director of the Institute |
Germany

Caroline Schmutte

Wellcome Trust |
Germany Office Lead |
Germany

Birgit Pickel

Federal Ministry for Economic
Cooperation and Development (BMZ) |
Global Health, Pandemic Prevention,
One Health | Director |
Germany



Walter
Bruchhausen



Achim
Hörauf



Johanna
Hanefeld



Caroline
Schmutte

WS 08

SAAL 5 | OCEANIA
9:00 – 10:30



Federal Ministry
for Economic Cooperation
and Development

THE LANCET

WORKSHOP

PANDEMICS AND OPERATIONALIZING ONE HEALTH

Working within the Framework of the Global Action Plan for SDG 3

HOSTS

German Federal Ministry for Economic Cooperation and Development (BMZ)

The Lancet One Health Commission

In 2018 Germany, Norway and Ghana initiated the Global Action Plan (GAP) for SDG 3, signed by 12 mainly UN Organizations. However the globally disruptive nature of infectious disease pandemics of zoonotic origin (COVID-19, Ebola and swine flu being recent examples), evidenced by their profound direct impact on global health, and compounded by economic and social effects, are a major threat to achieving SDG 3.

While recently emerging infectious diseases have come about through viruses jumping from wild animals to humans, pandemics can be fundamentally blamed on changes to relationships between humans and animals and to their shared environment. Domestic animals can be the source of zoonotic diseases such as tuberculosis or brucellosis but in addition livestock and wild animals may also act as bridges for the emergence of human

diseases. Domestic livestock can then serve as amplifying hosts for recent pathogen spillover events. Viruses can also mix in different domestic animal compartments and interact with human viruses to produce highly pathogenic human viruses (i.e. Influenza viruses). The frequency, intensity and impact of these pandemics and their effect on global health is closely interlinked with several factors, including global trade and mobility, climate change, antimicrobial resistance and an increase in the burden of non-communicable diseases.

For the GAP to be successful in helping to achieve SDG 3, it requires coordinated and efficient action across multiple disciplines and sectors which takes into account the risk of pandemics and how quickly they can roll back any progress made. In addition to defined commitments and proposed actions in the GAP

to improve inter-institutional cooperation and thus the situation of countries implementing SDG 3, One Health provides a platform for harnessing the complexity of the human-animal-environment interface in which these global health threats are implicated for achieving the SDGs.

In two sessions at the World Health Summit 2019, The Lancet One Health Commission undertook a Health consensus-seeking mission on the concept of One Health, and examined the potential of One Health to catalyze the paradigm

shift that the GAP demands and accelerate progress towards SDG 3. At this year's World Health Summit, The Lancet One Health Commission will further explore how to operationalize One Health in a sustainable way to address pandemics and ultimately SDG 3 through the GAP—involving the community/grassroots, health professionals, scientists, researchers and academia across disciplines, the next generation of students and young professionals, and at the political level.

CHAIRS

John Amuasi

Lancet Commission on One Health |
Co-Chair | Ghana

Andrea Winkler

Lancet Commission on One Health |
Co-Chair | Germany

SPEAKERS

Maria Flachsbarth

Federal Ministry for Economic
Cooperation and Development (BMZ) |
Parliamentary State Secretary |
Germany

Jean Scheftsik de Szolnok

Boehringer Ingelheim Pharma GmbH
& Co. KG | Member of the Board of
Managing Directors and Head of the
Animal Health Business Unit |
Germany

Anthony Nsiah-Asare

Office of the President |
Presidential Advisor on Health |
Ghana

Camilla Stoltenberg

Norwegian Institute of Public Health |
Director-General | Norway

Lothar H. Wieler

Robert Koch Institute (RKI) | President |
Germany



Maria
Flachsbarth



Camilla
Stoltenberg



John
Amuasi



Lothar H.
Wieler



Jean Scheftsik
de Szolnok



Andrea
Winkler



Anthony
Nsiah-Asare

KEY 03

SAAL 1
RUDOLF VIRCHOW
11:00 – 12:30



KEYNOTE

STRENGTHENING THE
ROLE OF THE EUROPEAN UNION
IN GLOBAL HEALTH

HOSTS

German Federal Ministry of Health (BMG)

Germany's Presidency of the Council of the European Union

In recent years, Germany has strengthened its commitment to global health, leveraging its G7 and G20 presidencies and lending support to multilateral and bilateral health partnerships. It has also become one of the strongest supporters of the World Health Organization and other international agencies. Germany has announced that global health will be

a priority during its 2020 EU presidency, in cooperation with its trio-partners Portugal and Slovenia. This presents a significant opportunity to help identify interventions in areas like development, health, research, environment, and trade that all EU members can implement to achieve SDG 3.

CHAIR

Ilona Kickbusch
The Graduate Institute of International and Development Studies |
Global Health Center | Chair of the International Advisory Board |
Switzerland

SPEAKERS

Jens Spahn
Federal Ministry of Health (BMG) |
Federal Minister of Health |
Germany

Marta Temido
Ministry of Health |
Minister of Health |
Portugal

Tomaž Gantar
Ministry of Health |
Minister of Health |
Slovenia

Bernhard Schwartländer
World Health Organization (WHO) |
Chief of Staff



Jens
Spahn

Bernhard
Schwartländer



Marta
Temido

Ilona
Kickbusch



Tomaž
Gantar

PD 13

SAAL 6 | EUROPE
11:00 – 12:30



PANEL DISCUSSION

SETTING A NEW AGENDA FOR WOMEN AND CANCER

HOST

Roche

Women are the cornerstone of all societies—in families, healthcare, communities and the workplace. They not only face unique challenges in maternal and reproductive health, but even in diseases not unique to women, they often have poorer outcomes. Perhaps most critically, NCDs have been the leading cause of women's mortality for decades. In cancer, for example, in addition to the 8.5 million newly diagnosed cases a year, the lion's share of family and community care falls on women the world over. The women's perspective has not been central to policy decision making and we have been slow

to recognize and act upon the importance of the role of women.

Now, with the unprecedented disruption brought by COVID-19, how can we look to the future to support an agenda and initiatives that positively support women's health moving forward?

In this session Roche will bring together experts from the public and private sectors to assess the current status of women's health, particularly in regard to cancer.

CHAIR

Shiulie Ghosh

Aero Productions | International Journalist, TV Presenter, Writer and Moderator | United Kingdom

SPEAKERS

Cecilia Bonefeld-Dahl

DIGITALEUROPE | Director-General | Belgium

Maira Caleffi

Hospital Moinhos de Vento | Chief of Breast Cancer Center Núcleo Mama Moinhos | Brazil

Teresa Graham

Roche Pharmaceuticals | Head of Global Product Strategy | Switzerland

Anja Mehnert

University of Leipzig | Medical Psychology and Medical Sociology and Division of Psychosocial Oncology | Chair | Germany

Isabel Mestres

City Cancer Challenge | Global Public Affairs | Director | Switzerland



Cecilia Bonefeld-Dahl



Teresa Graham



Maira Caleffi



Anja Mehnert



Shiulie Ghosh



Isabel Mestres

WS 09

SAAL 4 | AFRICA
11:00 – 12:30

**German Alliance for
Global Health Research**



Federal Ministry
of Education
and Research

WORKSHOP

EVIDENCE-BASED DECISION-MAKING IN GLOBAL HEALTH

What is Evidence and How is it Used in Making Decisions about COVID-19

HOSTS

German Alliance for Global Health Research

German Federal Ministry of Education and Research (BMBF)

COVID-19 has sparked a lively societal discourse about the relationship between science and policy in numerous countries affected and on a global level. The session examines the role and contributions of different research disciplines (virology, intensive care medicine, epidemiology, sociology, economy, ethics, etc.) at

different stages of the pandemic as well as the different types of evidence that researchers provide and politicians and authorities base their decision on (e.g. individual publications and reviews). It furthermore sheds light on different models of research- policy relationships and mutual influence.

CHAIRS

Eva Rehfuess
Ludwig-Maximilians-Universität München
(LMU Munich) | Chair of Public Health
and Health Services Research |
Germany

Maike Voss
German Institute for International
and Security Affairs (SWP) |
Scientist |
Germany

SPEAKERS

Yvonne Doyle
Public Health England | Medical Director
and Director for Health Protection |
United Kingdom

Christian Drosten
Charité – Universitätsmedizin Berlin |
Institute of Virology Campus Charité
Mitte | Director of the Institute |
Germany

Frode Forland
Norwegian Institute of Public Health |
Infectious Diseases and Global Health |
Specialist Director |
Norway

Fernando Simón
Ministry of Health |
Coordination Centre for Health Alerts
and Emergencies | Director |
Spain

Soumya Swaminathan
World Health Organization (WHO) |
Chief Scientist



Yvonne
Doyle



Fernando
Simón



Christian
Drosten



Soumya
Swaminathan



Frode
Forland



Maike
Voss



Eva
Rehfuess

WS 10

SAAL 5 | OCEANIA

11:00 – 12:30

Federal Ministry
of Education
and Research**INFECT
CONTROL****WORKSHOP****INFECTCONTROL—INVESTING IN THE
ONE HEALTH APPROACH**

A Federally Funded Initiative that Overcomes Barriers between Sectors and Disciplines to Prevent, Quickly Diagnose, and Effectively Fight Infectious Diseases

HOSTS**German Federal Ministry of Education and Research (BMBF)****InfectControl**

Why is it necessary that medical doctors and infection biologists join forces with veterinarians, architects, climate-, material- and communication scientists to fight infections?

The workshop gives an overview about the German-wide, BMBF-funded research program InfectControl and introduces some of its flagship projects. It is a unique collaboration in Germany involving experts from a wide range of disciplines and specialist areas. Together, they fight infections that affect Germany and Europe in particular following the One Health approach with the aim to sustainably prevent infectious diseases, to detect them faster and to fight them comprehensively.

To prevent infectious diseases, InfectControl supports educational campaigns as well as the development of new techniques and standards, e.g. for patient rooms in

hospitals. For a better and faster diagnosis of infectious diseases the consortium is developing new rapid tests for specific pathogens and new analysis methods.

InfectControl also promotes the development of vaccines and drugs. In collaboration with the German Center for Infectious Research (DZIF), InfectControl currently develops a new tuberculosis drug (clinical phase IIa) that has a completely new mode of action and is also effective against resistant strains.

In the workshop, members of the consortium will present prominent results from their interdisciplinary projects. Following the presentations the InfectControl consortium will discuss with the audience the hurdles and future perspectives for One Health initiatives that are necessary to fight infectious diseases.

CHAIR

Axel Brakhage

Leibniz Institute for Natural Product Research and Infection Biology –
Hans Knöll Institute (Leibniz-HKI) | Director |
Germany

SPEAKERS

Petra Gastmeier

Charité – Universitätsmedizin Berlin |
Institute for Hygiene and Environmental
Medicine | Director of the Institute |
Germany

Oliver Kurzai

Leibniz Institute for Natural Product
Research and Infection Biology –
Hans Knöll Institute (Leibniz-HKI) |
Professor and Chair |
Germany

Thomas C. Mettenleiter

Friedrich Loeffler Institute (FLI) |
President |
Germany

Peter Schmid

CEVA Animal Health |
Pharma Innovations |
Director of Pharma Innovations |
France

Wolfgang Sunder

Technical University of Braunschweig |
Institute for Industrial Construction
and Structural Design |
Head of Research |
Germany

Lothar H. Wieler

Robert Koch Institute (RKI) |
President |
Germany



Axel
Brakhage



Peter
Schmid



Petra
Gastmeier



Wolfgang
Sunder



Oliver
Kurzai



Lothar H.
Wieler



Thomas C.
Mettenleiter

PD 14

SAAL 10 | ASIA

12:30 – 14:00

PANEL DISCUSSION

CLIMATE CHANGE
AND HEALTH

IAP Project Regional Assessment



HOSTS

Association of Academies and Societies of Sciences in Asia (AASSA)**Inter-American Network of Academies of Science (IANAS)****InterAcademy Partnership (IAP)****The Network of African Science Academies (NASAC)**

There are many pathways, direct and indirect, mediating the effects of climate change on human health. There is significant variation within and between regions and amongst different population groups. While there is also increasing political awareness of the issues and a rapidly accumulating evidence base, there has been less focus on solutions: how to develop resilience, adaptation in health systems and health co-benefits of climate change mitigation.

The IAP project (<https://www.interacademies.net/project/climate-change-and-health>), aiming to inform policy-makers and other stakeholders, is progressing in parallel with the regional academy networks in Africa (NASAC), Asia (AASSA)

and the Americas (IANAS), building on previous work done in Europe (EASAC). The regional outputs will all be published by early 2021, to be followed by a global synthesis report to explore regional similarities and differences, inter-regional issues and global priorities.

The session invites regional perspectives (virtual) from academy network experts on emerging issues and on key points that require further exploration. Discussion with the audience worldwide will be encouraged to help ensure that a wide range of inputs is captured by the project, also providing national, regional and global perspectives in preparation for COP 26.

CHAIR

Volker ter Meulen

Julius Maximilians University of Wuerzburg |
President of IAP and Co-Chair of IAP Project |
Germany

SPEAKERS

Khairul Abdullah

MAHSA University |
AASSA Working Group Chair |
Malaysia

Robin Fears

InterAcademy Partnership (IAP) |
Project Coordinator |
Italy

Sir Andrew Haines

London School of Hygiene and
Tropical Medicine (LSHTM) |
IAP Project Co-Chair |
United Kingdom

Jeremy McNeill

University of Western Ontario |
IANAS Working Group Chair |
Canada

Volker ter Meulen

Julius Maximilians University
of Wuerzburg | President of IAP
and Co-Chair of IAP Project |
Germany

Caradee Wright

South African Medical Research
Council (SAMRC) |
NASAC Working Group Chair |
South Africa



Khairul
Abdullah



Jeremy
McNeill



Robin
Fears



Volker
ter Meulen



Sir Andrew
Haines



Caradee
Wright

PD 15

SAAL 2 | AMERICA
12:30 – 14:00



PANEL DISCUSSION

YOUTH PERSPECTIVES ON HEALTH

COVID-19 and Gender Engagement

HOST

International Federation of Medical Students' Associations (IFMSA)

Today, youth constitute more than 1.8 billion people living on earth, representing one-third of the population and a high percentage of the health workforce.

The session will bring together young and senior stakeholders from academia, international development, government, NGOs and private sector, who work on initiatives tackling the uncertainty of COVID-19 crisis. It will have two parts:

First an interactive panel will serve as both a space to share the challenges youth face amidst the unprecedented

pandemic as well as best practices on youth taking the lead on COVID-19 response not only in healthcare but also in the communities.

In the second part of the event, the speakers will share their reflections on the most urgent questions in the face of pandemic, including the gender lens and exacerbation of inequalities revealed. Moreover, the event will allow young people to network and participate in the “meet-and-greet” session as the official closing of the session.

CHAIR

Eglė Janušonytė

International Federation of Medical Students' Associations (IFMSA) |
Vice President for External Affairs 2020/2021 |
Denmark

SPEAKERS

Hera Ali

International Pharmaceutical
Students' Federation |
Chairperson of Public Health |
United Kingdom

Ieva Berankytė

International Federation of
Medical Students' Associations
(IFMSA) | Liaison Officer for
Sexual and Reproductive Health
and Rights Issues |
Denmark

Martin Blohmer

Young Leaders for Health |
Representative |
Germany

Nicole De Paula

Women Leaders for Planetary
Health - IASS Potsdam |
Executive Director and Founder |
Germany

Omnia El Omrani

International Federation of
Medical Students' Associations
(IFMSA) | Liaison Officer for
Public Health Issues |
Denmark

Shymaa Enany

Suez Canal University |
Department of Microbiology
and Immunology |
Associate Professor | Egypt

Caline Mattar

Global Health Workforce
Youth Hub | Chair |
United States of America

Tugce Schmitt

Global Health Next Generation
Network | Representative |
Belgium

Zsófia Szlamka

Global Shapers Community |
Global Shapers Cambridge |
Curator and Co-founder
of VOICES | United Kingdom



Ieva
Berankytė



Omnia
El Omrani



Caline
Mattar



Martin
Blohmer



Shymaa
Enany



Tugce
Schmitt



Nicole
De Paula



Eglė
Janušonytė



Zsófia
Szlamka

KEY 04

SAAL 1
RUDOLF VIRCHOW
14:00 – 15:30

KEYNOTE

PANDEMIC PREPAREDNESS
IN THE AGE OF COVID-19

Global Cooperation not Competition

HOSTS

Charité – Universitätsmedizin Berlin

Foundation for Innovative New Diagnostics (FIND)

London School of Hygiene & Tropical Medicine (LSHTM)

M8 Alliance



COVID-19 has called our global pandemic preparedness into question. But building on experience with other coronaviruses, including SARS and MERS, and learning lessons from combatting outbreak diseases including Ebola, progress is being made with unprecedented speed to develop the tests, treatments and vaccines needed to keep the world

safe. New forms of collaboration and strengthened partnerships have emerged as central to the response. From science and research to policy and implementation, the world has shifted in terms of our ability to react. How can we build back better after COVID-19, and ensure preparedness for the future?

CHAIR

Catharina Boehme
Foundation for Innovative New Diagnostics (FIND) | CEO | Switzerland

SPEAKERS

Thomas Cueni
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Director-General | Switzerland

Christian Drosten
Charité – Universitätsmedizin Berlin | Institute of Virology Campus Charité Mitte | Director of the Institute | Germany

Tom Frieden
Resolve to Save Lives | President and CEO | United States of America

Jayasree K. Iyer
Access to Medicine Foundation | Executive Director | The Netherlands

Peter Piot
London School of Hygiene and Tropical Medicine (LSHTM) | Director and Professor of Global Health | United Kingdom



Catharina Boehme Tom Frieden



Thomas Cueni Jayasree K. Iyer



Christian Drosten Peter Piot

PD 16

SAAL 6 | EUROPE
14:00 – 15:30



varian

PANEL DISCUSSION

RADIATION THERAPY AS AN ESSENTIAL
COMPONENT OF CANCER CONTROL

Understanding how Innovations are Driving Uptake and Impact
in Low- and Middle-Income Countries (LMICs)

HOSTS

International Atomic Energy Agency (IAEA)

Varian Medical Systems

The 43.8 million persons living with cancer who were diagnosed within the last 5 years demonstrate that cancer is a substantial global social and economic burden. In all countries, regardless of development. The International Agency for Research on Cancer (IARC) projects that (by 2030), over 24 million people will be diagnosed with cancer worldwide and 13 million will die from the disease every year. The rising cancer burden hits low and middle income countries (LMICs) the hardest, many of which are ill-equipped to deal with the present situation, reflected in disparities in cancer survival and survivorship. The extent of implementation of national cancer control plans has increased in recent years, allowing access to health technologies such as radiotherapy for quality and cost-effective treatment for millions of cancer patients for the first time. This is particularly pertinent

for women in LMICs countries who suffer over 90% of all global deaths due to cervical and 70% due to breast cancer (Globocan 2018).

Mobile technology, artificial intelligence (AI) and other emerging technologies are rapidly changing the delivery of healthcare worldwide. This panel discussion will share experiences of implementing essential radiotherapy services and explore how innovative healthcare solutions in this domain are contributing to increasing access to safe, effective, affordable and sustainable treatment services for cancer patients in LMICs. Successful strategic partnerships between Governments, international institutions and the private sector will be showcased and representatives from the IAEA, Varian, Ministries of Health and clinical experts will describe how new technologies can further close

the access gap and improve outcomes for patients as well as address the challenge of shortage of medical cancer care professionals, in support of the Agenda

2030 and the newly adopted WHO Global Strategy towards elimination of cervical cancer as a public health problem.

CHAIR

Julie Torode

Union for International Cancer Control (UICC) |
Deputy CEO and Director of Advocacy and Networks |
Switzerland

SPEAKERS

Supriya Chopra

Tata Memorial Centre |
Associate Professor Radiation Oncology |
India

Rafael Mariano Grossi

International Atomic Energy Agency (IAEA) | Director-General

Bello Abubakar Mohammed

Consultant Clinical Oncologist |
National Hospital |
Nigeria

Dow R. Wilson

Varian Medical Systems |
President and CEO |
United States of America



Supriya
Chopra



Julie
Torode



Rafael Mariano
Grossi



Dow R.
Wilson

WS 11

SAAL 4 | AFRICA

14:00 – 15:30

vfa Die forschenden
Pharma-Unternehmen
Research-Based
Pharmaceutical Companies

EBERHARD KARLS
UNIVERSITÄT
TÜBINGEN

**DEUTSCHES
NETZWERK**
gegen vernachlässigte
Tropenkrankheiten
(DNTDs)

DTG

Universitätsklinikum
Tübingen

WORKSHOP

NTDS AND CHALLENGES OF THE COVID-19 CRISIS

How Neglected Tropical Diseases can Contribute to Overcoming
Impact and Risks from COVID-19

HOSTS

Association of Research-based Pharmaceutical Companies (vfa)

Eberhard Karls University Tuebingen

German Network against Neglected Tropical Diseases (DNTDs)

German Society for Tropical Medicine and International Health (DTG)

University Hospital Tuebingen

The COVID-19 pandemic has affected the progress towards elimination of Neglected Tropical Diseases (NTDs) in a dramatic way: Following the initial recommendations of WHO, the implementation of NTD-programs had been suspended but a differentiated decision-making framework for recommencing mass treatment and other NTD interventions is now in place. This means that annual mass drug administration cycles were interrupted, no monitoring and evaluation was done, and little to no operational research implemented. If COVID-19 disrupts NTD-interventions for a longer period, the

likelihood that the burden of NTDs will increase again and many years of efforts will be lost, is high. The NTD-community has to adapt programs and guidelines facing the challenges of the COVID-19 pandemic and continue the pathway to elimination of NTDs at the same time. Since NTD-programs are providing unique platforms that are reaching out to all communities in their target areas, assuring prevention and treatment including to those who often don't have access to health care can also benefit the fight against COVID-19.

CHAIRS

Achim Hörauf

University Hospital Bonn |
Institute of Medical Microbiology,
Immunology and Parasitology |
Director of the Institute |
Germany

Carsten Köhler

University Hospital Tuebingen |
Center of Competence at Institute for
Tropical Medicine, Travel Medicine
and Human Parasitology |
Director of Center of Competence |
Germany

SPEAKERS

Irene Ayakaka

Makerere University College of Health
Sciences | Uganda Tuberculosis
Implementation Research Consortium
(U-TIRC) | Project Manager |
Uganda

Constanze Bönig

Vétérinaires Sans Frontières Germany |
Desk Officer HQ for Humanitarian Aid &
Development Cooperation |
Germany

Mwelecele Ntuli Malecela

World Health Organization (WHO) |
WHO Regional Office for Africa |
Director of Department of Control of
Neglected Tropical Diseases |
Congo

Johannes Waltz

Merck | Global Schistosomiasis
Alliance (GSA) | Head of Merck
Schistosomiasis Elimination Program |
Germany

Makoy Yibi Logora

CBM South Sudan |
National NTD Coordinator |
South Sudan



Irene
Ayakaka



Carsten
Köhler



Constanze
Bönig



Mwelecele Ntuli
Malecela



Achim
Hörauf



Johannes
Waltz

WS 12

SAAL 5 | OCEANIA
14:00 – 15:30



WORKSHOP

VACCINATION AND TRANSMISSION CONTROL

What's New and What Works in Preventing Infections

HOSTS

Leibniz Association

Research Center Borstel – Leibniz Lung Center

Vaccination against and control of vector-borne transmission of infectious agents are prime staples of infection control. The speakers in this session will present their exemplary experience with the development of novel vaccines (tuberculosis, ebola), the acceptance of vaccination in the population, or with imple-

menting vector control measures (dengue, malaria). The goal is to distill, from these diverse experiences, a consensus on what works best and what doesn't work in infection control, and to discuss best practice examples for overcoming obstacles identified by the speakers.

CHAIR

Stefan Ehlers

Research Center Borstel – Leibniz Lung Center | CEO | Germany

SPEAKERS

Marylyn Addo

Medical Center Hamburg-Eppendorf |
Head of Division of Infectious Diseases |
Germany

John Amuasi

Lancet Commission on One Health |
Co-Chair |
Ghana

Stefan H.E. Kaufmann

Max Planck Institute for Infection Biology |
Director Emeritus |
Germany

Steven Sinkins

University of Glasgow |
Centre for Virus Research | Professor
in Microbiology and Tropical Medicine |
United Kingdom



Marylyn
Addo

Stefan H.E.
Kaufmann



John
Amuasi

Steven
Sinkins



Stefan
Ehlers

PD 17

Live | SAAL 1
RUDOLF VIRCHOW

Overflow | SAAL 6
EUROPE

16:00 – 17:30



International Federation
of Pharmaceutical
Manufacturers & Associations

PANEL DISCUSSION

PERSPECTIVES FROM THE COVID-19 PANDEMIC

The Importance of Innovation in Maintaining Global Health Security

HOST

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

Despite the huge societal costs of Anti-microbial Resistance (AMR), there is no viable market for new antibiotics. As a result, important antibiotics in the early stages of development may never reach patients due to a lack of funding for the later stages of clinical research. To bridge this funding gap, over 20 leading pharmaceutical companies recently launched a ground-breaking partnership to invest nearly \$1 billion through a new AMR Action Fund that aims to bring 2 to 4 new antibiotics to patients by the end of the decade.

Both COVID-19 and AMR are significant global health threats that necessitate action by all stakeholders in order to be tackled successfully. Yet there are differences—unlike COVID-19, AMR is a predictable and preventable threat that is not new. Continuous innovation in time, and in preparation of, a global pandemic to address current and future global health crises is therefore essential.

Stepping up to the challenge of AMR, the Fund will invest in smaller biotech companies focused on developing novel antibiotics that address the highest priority public health needs, make a significant difference in clinical practice, and save lives. While the Fund seeks to make significant tangible progress in the fight against AMR, it alone will not be sufficient to solve the challenge, and broader policy reforms will be necessary to create an environment that encourages long-term investment into antibiotic R&D and rewards innovation.

This session will explore the new biopharmaceutical industry initiative, the importance of innovation to maintain global health security as also evidenced by COVID-19, as well as foster discussion on what is needed for a sustainable antibiotic innovation ecosystem.

CHAIR

Astrid Frohloff
Journalist | Germany

SPEAKERS

Francesca Colombo
Organization for Economic Cooperation
and Development (OECD) |
Head of the Health Division |
France

Thomas Cueni
International Federation of Pharma-
ceutical Manufacturers & Associations
(IFPMA) | Director-General |
Switzerland

Tim Jinks
Wellcome Trust | Head of Drug Resistant
Infections Priority Program |
United Kingdom

Stefan Oelrich
Bayer AG |
Member of the Board of Management
President Pharmaceuticals |
Germany

Lord Bethell of Romford
Parliament of the United Kingdom |
Parliamentary Under Secretary of State |
Minister for Innovation |
United Kingdom



Francesca
Colombo



Tim
Jinks



Thomas
Cueni



Stefan
Oelrich



Astrid
Frohloff



Lord
Bethell of Romford

PD 18

SAAL 10 | ASIA
16:00 – 17:30



Leopoldina
Nationale Akademie
der Wissenschaften



THE LANCET

PANEL DISCUSSION

CLIMATE CHANGE AND ONE HEALTH

Critical Action for a Sustainable Planet

HOSTS

German National Academy of Sciences Leopoldina

InterAcademy Partnership (IAP)

The Lancet One Health Commission

Now more than ever before, the world has been awakened to the threat posed by diseases which are closely linked to human-animal-environment interaction, and which have far-reaching global health and socio-economic implications. There is overwhelming consensus on the components of One Health involving human animals, non-human animals, and the environment. As both human and non-human animals fundamentally cannot exist outside of an environment, which they are an integral part of and share, shared spaces need to be managed. Therefore, an imbalance in activity by any party within a shared space puts that space in jeopardy of unsustainability.

Destructive human and animal (often via humans) activity within the shared envi-

ronment has been shown to have direct impact on climate, which in turn impacts negatively and directly on the shared environment, animals and humans. This complex negative cycle links Climate Change very tightly to One Health.

In this session, we propose to discuss in-depth, the importance of climate change, considering the current global awareness and movement around the subject, to One Health within the context of global pandemics. The discussion will explore how the linkages extricated between One Health and Climate Change can be translated into global, regional and national policies and actions to promote a healthy and sustainable reconnected future for our planet.

CHAIR

Gerald Haug
German National Academy of Sciences Leopoldina | President | Germany

SPEAKERS

John Amuasi
Lancet Commission on One Health |
Co-Chair |
Ghana

Tony Capon
Monash University | Sustainable
Development Institute | Director |
Australia

Sabine Gabrysch
Charité – Universitätsmedizin Berlin |
Professor for Climate Change and Health |
Germany

Benjamin Roche
French National Research Institute
for Sustainable Development (IRD) |
Infectious Diseases and Vectors:
Ecology, Genetics, Evolution and Control
(mivegec) | Research Director |
France

Andrea Winkler
Lancet Commission on One Health |
Co-Chair |
Germany



John
Amuasi

Gerald
Haug



Tony
Capon

Benjamin
Roche



Sabine
Gabrysch

Andrea
Winkler

PD 19

SAAL 2 | AMERICA
16:00 – 17:30



PANEL DISCUSSION

ESSENTIAL SURGICAL AND TRAUMA CARE

An Integral Part of Universal Health Coverage

HOSTS

AO Alliance Foundation

Program in Global Surgery and Social Change of the Harvard Medical School

Although increasingly recognized as an indivisible, indispensable part of Universal Health Coverage, limited progress has been made in recent years to advance surgical care around the world. Surgical conditions make up over five times the mortality of HIV/AIDS, tuberculosis, and malaria combined, yet funding for surgical care remains inequitably small in terms of international funding. This despite the fact that today, over five billion people remain without access to safe surgical care.

The result: over 17 million preventable deaths annually and 30% of the global burden of disease is attributable to surgical conditions. Furthermore, trauma and injury accounts for 5.8 million deaths

and around 50 million permanently disabled persons per year. 90% of this mortality and morbidity occurs in LMICs. To address this, we need integrated and holistic approaches to build up health systems that includes increased emphasis on surgical delivery, an emphasis that is currently lacking.

We must recognize that the old-fashioned myth that access to emergency and essential surgical care is a luxury item has been debunked. On the contrary, emergency and essential surgical interventions are cost-effective and absolutely essential for Universal Health Coverage.

CHAIR

John G. Meara
Harvard Medical School |
Professor of Surgery |
United States of America

Geoffrey Ibbotson
Global Surgery Foundation |
Executive Lead |
Switzerland

SPEAKERS


Jim Harrison
AO Alliance Foundation |
African Regional Director |
Switzerland

Ali Jafarian
Tehran University of Medical Sciences
(TUMS) | Former Chancellor |
Iran

Teri Reynolds
World Health Organization (WHO) |
Clinical Services and Systems –
Integrated Health Services | Unit Head

Lubna Samad
Indus Health Network |
Director of Center for Essential
Surgical and Acute Care |
Pakistan

H.E. Ifereimi Waqainabete
Fijian Government |
Minister for Health and Medical Services |
Fiji



Jim
Harrison

Teri
Reynolds



Ali
Jafarian

Lubna
Samad



John G.
Meara

H.E. Ifereimi
Waqainabete

WS 13

SAAL 4 | AFRICA

16:00 – 17:30

**WORKSHOP****‘BUILDING BACK BETTER’
WITH SMART INVESTMENTS IN NCDs****A Post COVID-19 Imperative****HOSTS****NCD Alliance****Sanofi**

People living with noncommunicable diseases (NCDs), such as cardiovascular and respiratory diseases, diabetes or cancer, have been at increased risk of severe illness and death due to the COVID-19 pandemic, revealing how vulnerable these groups are. The WHO Rapid assessment of service delivery for NCDs during the COVID-19 pandemic has found that the COVID-19 pandemic has ‘severely’ disrupted the delivery of services to prevent and treat NCDs in almost 80% of countries surveyed. Therefore, the interaction between COVID-19 and NCDs revealed how crucial it is to address the underlying drivers of the NCD pandemic that are fuelling COVID-19 mortality.

At the same time, while health systems are facing the most serious global pandemic crisis in a century, the latter has amplified the historical investment gap in NCDs and the underlying shortcomings of health systems to respond to the healthcare need of people living with or at risk of NCDs. It has highlighted the urgent need of political will to invest in NCD prevention and in strong health systems and primary healthcare as the best defence against outbreaks like COVID-19.

In this context, this workshop will bring the unique expertise of governments, civil society, people living with NCDs and industry around the table to discuss the lessons learned from the crisis and the breadth of the long-term approach and investments needed to ensure a sustainable response to NCDs.

CHAIR

Nina Renshaw
The NCD Alliance | Director of Policy and Advocacy | Switzerland

SPEAKERS

Funmi Adewara
Mobihealth International |
Founder and CEO |
United Kingdom

Christopher Agbega
People Living with NCDs (PLWNCDs) |
Representative |
Ghana

Ricardo Baptista Leite
UNITE | Founder and President |
Portugal

Marc-Antoine Lucchini
Sanofi | Head of International
General Medicine |
France

Bente Mikkelsen
World Health Organization (WHO) |
Division of Noncommunicable Diseases
and Promoting Health through the
Life-course | Director



Funmi
Adewara

Marc-Antoine
Lucchini



Christopher
Agbega

Bente
Mikkelsen



Ricardo
Baptista Leite

Nina
Renshaw

WS 14

SAAL 5 | OCEANIA
16:00 – 17:30



WORKSHOP

OVERCOMING CULTURAL BARRIERS THROUGH RESPECT AND DIALOGUE

HOSTS

InterAcademy Partnership (IAP)

M8 Alliance

Sustainable peace is the central aim of the Sustainable Development Goals (SDGs) and a necessary basis for all SDGs, including “Good Health and Well-being”. The initiative “Respect and Dialogue” by the InterAcademy Partnership (IAP) intends to give science a stronger voice and take more responsibility in this regards. Many global crises are born or worsened by the lack of comprehension, and limited interest and courage to reach out across borders. Using health as an entry point, the “Respect and Dialogue” initiative wants to tackle barriers of different natures—gathering different sectors,

disciplines and cultures—and address how they can be overcome to achieve progress towards the SDG objectives.

In response to the ongoing COVID-19 pandemic, we have witnessed instances of dialogue and respect for each other’s perspectives, and at times a noticeable lack thereof. In this year’s session we will look at these instances, and more importantly what lessons are to be learned in the continuous efforts to handle this pandemic and other global health challenges.

CHAIRS

Edelgard Bulmahn
German Bundestag | Former Federal
Minister and former Vice President |
Germany

Roberto Francesco Monti
Respect and Dialogue |
Senior Advisor |
Italy

SPEAKERS

Tolullah Oni
University of Cambridge |
Senior Research Medical Officer |
United Kingdom

Clara Cruz Santos
Coimbra University |
Professor of Social Work |
Portugal

Neera Tanden
Center for American Progress |
President and CEO |
United States of America

Justin Vaïsse
Paris Peace Forum |
Director-General |
France

Moneef R. Zou’bi
InterAction Council |
Science Advisor |
Jordan



Edelgard
Bulmahn



Neera
Tanden



Roberto Francesco
Monti



Justin
Vaïsse



Tolullah
Oni



Moneef R.
Zou’bi



Clara Cruz
Santos

PROGRAM

TUESDAY, OCTOBER 27

PD 20**Live | SAAL 1**
RUDOLF VIRCHOW**Overflow | SAAL 6**
EUROPE**9:00 – 10:30**

PANEL DISCUSSION

**COVID 50/50:
WOMEN LEADING IN CRISIS****A Gender Responsive Approach**

HOST**Women in Global Health**

Gender equality makes global health stronger. This session will explore women's leadership and gender-responsive health systems during COVID-19. Most countries report higher COVID-19 mortality amongst men than women but women face greater risks because they are the majority of frontline health workers, are typically the primary caregivers of the sick, and have a greater socioeconomic vulnerability. Women leaders tend to be decisive, listen to expert evidence, focus on people and

communicate honestly with the public. Yet, few women are included in health security decision-making, including task forces, working groups, and political and scientific committees for the pandemic response. The participation of women, their leadership and the breadth of their experience and perspectives is critical to the response. Analysis of women leaders during COVID-19 has shown that women have used a more collaborative, transparent and whole of society approach.

CHAIRS

Roopa Dhatt
Women in Global Health |
Executive Director |
United States of America

Sarah Hillware
Women in Global Health |
Deputy Director |
United States of America

SPEAKERS

Margaret Chan
Boao Forum For Asia | President

Francesca Colombo
Organization for Economic Cooperation
and Development (OECD) |
Head of the Health Division |
France

Ester Cedeira Sabino
University of São Paulo |
Faculty of Medicine |
Associate Professor |
Brazil

Elhadj As Sy
Kofi Annan Foundation |
Chair of the Board |
Switzerland

Clare Wenham
London School of Economics and
Political Science | Assistant Professor
of Global Health Policy |
United Kingdom



Margaret
Chan



Sarah
Hillware



Francesca
Colombo



Elhadj As
Sy



Roopa
Dhatt



Clare
Wenham

PD 21

SAAL 10 | ASIA
9:00 – 10:30



Federal Ministry
of Health



World Health
Organization

PANEL DISCUSSION

DECADE OF ACTION: ACCELERATING PROGRESS ON THE HEALTH-RELATED SDGs AT COUNTRY LEVEL

Leveraging the Global Action Plan for Healthy Lives and
Well-being for All in countries in times of COVID-19

HOSTS

German Federal Ministry of Health (BMG)

World Health Organization (WHO)

By committing to the Global Action Plan for Healthy Lives and Well-being for All (GAP), the signatory agencies signaled their readiness to better support countries during the decade of action on the SDGs. COVID-19 has set countries back on their path to achieving the health-related SDGs and has further emphasized the importance of joint support to countries.

The GAP's comparative advantage is to strengthen continuous, effective, long-term collaboration and alignment among a set of UN and non-UN multilateral agencies in support of countries' nationally defined needs, priorities and plans. Country ownership and leadership lie at the heart of GAP's success and clear priorities for action to accelerate progress towards the health-related SDGs have been identified by around a dozen coun-

tries under the auspices of the GAP, with expressions of interest from many more.

This panel debate will present what countries are doing to get back on track and/or accelerate progress towards health-related SDGs as they respond and recover from COVID-19. It will feature representatives of countries engaged or interested in the implementation of the GAP and hear about their experiences so far and what they expect from the GAP agencies in terms of joined-up support. The panel will share updates on the collaboration; review lessons learned and challenges encountered in the implementation of the GAP to date and discuss how successful approaches could be replicated in more countries. The debate will also highlight how other stakeholders at country level can engage and contribute to the process.

CHAIR

Suraya Dalil
World Health Organization (WHO) | PHC Special Programme | Director

SPEAKERS

Kwaku Agyeman-Manu
Minister for Health |
Ghana

Cecilia Lodunu-Senoo
Founder and Executive Director of Hope
for Future Generations (HFFG) |
Ghana

Muhsinzoda Gafur Muhsin
Ministry of Health and Social Protection |
First Deputy Minister |
Tajikistan

Fawziya Abikar Nur
Ministry of Health |
Minister of Health and Human Services
Federal of the Republic of Somalia

Malik Muhammad Safi
Director General Health |
Ministry of National Health Services,
Regulation and Coordination, Govern-
ment |
Pakistan



Kwaku Agyeman-Manu Fawziya Abikar Nur



Cecilia Lodunu-Senoo Malik Muhammad Safi



Muhsinzoda Gafur Muhsin

PD 22

SAAL 2 | AMERICA
9:00 – 10:30



PANEL DISCUSSION

ACCESS TO ESSENTIAL MEDICINES IN LMICS

A Key Precondition to Achieving Universal Health Coverage

HOST

Medicines Patent Pool (MPP)

Limited access to essential medicines is one of the key barriers to health. This is particularly true for the majority of low-and middle-income countries (LMICs). The barriers are varied and include weak health systems, no or lack of proper infrastructure, insufficient numbers of health workers, insufficient knowledge among health workers, no surveillance systems, lack of diagnostics. Price, of course, is a key barrier.

The price of patented medicines is becoming an increasing challenge in all countries, but in LMICs the proportion of healthcare spend on medicines is higher, at least a quarter and up to 67% of the entire healthcare budget, and this continues to increase. As a result, the price

of medicines could make the implementation of Universal Health Coverage (UHC) unaffordable.

The answer to this challenge is to make medicines available and affordable, but the next question is how. A number of access models have been tried, including voluntary public health licensing, donation programs, tiered pricing, bilateral deals between originators and generic companies, and as a last resort compulsory or government licensing. The appropriateness of each model will depend on the specific circumstances but all should be judged against the major public health standards of transparency, sustainability, and benefit.

CHAIR

Charles Gore
Medicines Patent Pool (MPP) | Executive Director | United Kingdom

SPEAKERS

Graham Cooke
Imperial College |
Wright-Fleming Institute | NIHR Research
Professor of Infectious Diseases |
United Kingdom

Jayasree K. Iyer
Access to Medicine Foundation |
Executive Director |
The Netherlands

Maurine Murenga
Lean on Me Foundation |
Executive Director |
Kenya

Mariângela Simão
World Health Organization (WHO) |
Assistant Director General,
Access to Medicines, Vaccines
and Pharmaceuticals

Marisol Touraine
Unitaid |
Chair of the Executive Board



Graham
Cooke



Maurine
Murenga



Charles
Gore



Mariângela
Simão



Jayasree K.
Iyer



Marisol
Touraine

WS 15

SAAL 4 | AFRICA

9:00 – 10:30

MDC MAX DELBRÜCK CENTER
FOR MOLECULAR MEDICINE
BERLIN-BUCH
MEMBER OF THE HELMHOLTZ ASSOCIATION

WORKSHOP

CARDIOVASCULAR HEALTH

For the Many and the Few

HOST

Max Delbrück Center for Molecular Medicine (MDC)

Cardiovascular disease represents one of the major threats to human health. As longevity and prosperity increase globally, changing nutrition and a more sedentary life style drive increasing risk for acute and chronic cardiovascular disease. Whilst the costs for societies are steadily growing, research budgets and the emergence of new therapies do not keep pace. Consequently, the medical need and societal importance to advance both our understanding of fundamental pathomechanisms and to develop effective means to prevent and treat a 'pandemic' of heart failure and multiorgan damage associated with poor microvascular health is greater than ever before.

From the perspective of the individual, understanding the particular link between genetic predisposition, epigenetic imprinting of environmental and lifestyle related influences on cardiovascular tissues, and the specific manifestation or phenotypic spectrum appears to be

paramount for the development of personalized and highly effective/tailored treatments. From a population perspective, however, understanding global correlations, risk factors and preventive opportunities as well as generic treatment opportunities for this systems-wide pathology, with particular attention to the differing conditions in the regions of the world appears the most urgent demand.

This workshop therefore aims to portray on the one hand state-of-the art science approaches that unravel the epidemiology and population genetics/genomics, risk factors and global treatment options to benefit 'the many' and on the other hand those that dig deeper into the disease mechanisms of the individual to optimally treat 'the few'. Perspectives from international medical experts, epidemiologists, experimental researchers and pharma industry leaders will shape the discussion on emerging issues in cardiovascular health research.

CHAIRS**Holger Gerhardt**

Max Delbrück Center for
Molecular Medicine in the
Helmholtz Association (MDC) |
Head of Integrative Vascular Biology |
Germany

Joël Ménard

University of Paris Descartes |
Emeritus Professor of Public Health |
France

SPEAKERS**Ann Aerts**

Novartis Foundation | Head |
Switzerland

Sir Rory Edwards Collins

University of Oxford |
Clinical Trial Service Unit | Professor
of Medicine and Epidemiology |
United Kingdom

Gina Portella

EMERGENCY |
Medical Division Coordinator |
Italy

Karen Sliwa-Hahnle

The Hatter Institute for Cardiovascular
Research in Africa | Director |
South Africa



Ann
Aerts

Joël
Ménard



Sir Rory Edwards
Collins

Gina
Portella



Holger
Gerhardt

Karen
Sliwa-Hahnle

WS 16

SAAL 5 | OCEANIA
9:00 – 10:30



Federal Ministry
for Economic Cooperation
and Development

WORKSHOP

DEVELOPING STRATEGIES FOR FIGHTING COVID-19 AROUND THE WORLD

(PART 1)

HOST

German Federal Ministry for Economic Cooperation and Development (BMZ)

Even pandemics with global dimensions have local and regional origins. This high-level event under the patronage of the German Federal Ministry for Economic Cooperation and Development (BMZ) and Charité Universitätsmedizin Berlin is therefore intended to gather and exchange international experience from the fight against these kinds of risks. An international and multisectoral expert

panel will identify, present and discuss both technical principles and concrete operational measures from practice. As a result, a range of recommendations for future action will be formulated. Addressing the One Health approach, which especially in the course of the current pandemic, as multisectoral and holistic approach, has gained increasing attention, will be one practical example of the session.

CHAIR**Maria Flachsbarth**

Federal Ministry for Economic Cooperation and Development (BMZ) |
Parliamentary State Secretary |
Germany

SPEAKERS**Christian Drosten**

Charité – Universitätsmedizin Berlin |
Institute of Virology Campus Charité
Mitte | Director of the Institute |
Germany

Monique Eloit

OIE – World Organisation for
Animal Health | Director-General |
France

Thomas C. Mettenleiter

Friedrich Loeffler Institute (FLI) |
President |
Germany

Gerd Müller

Federal Ministry for Economic
Cooperation and Development (BMZ) |
Federal Minister for Economic
Cooperation and Development |
Germany



Christian
Drosten

Thomas C.
Mettenleiter



Monique
Eloit

Gerd
Müller



Maria
Flachsbarth

PD 23

Live | SAAL 1
RUDOLF VIRCHOW
Overflow | SAAL 6
EUROPE
11:00 – 12:30



ROBERT KOCH INSTITUT



PANEL DISCUSSION

GOARN 2020: CHANGING THE FACE OF OUTBREAK SUPPORT

20 Years of Global Outbreak Alert and Response Network

HOSTS

Global Outbreak Alert and Response Network (GOARN)

Robert Koch Institute (RKI)

World Health Organization (WHO)

In April 2000, outbreak response partners—UN agencies, international and Non-Governmental Organizations, public health agencies, technical networks and academia—were brought together by WHO to set up the Global Outbreak Alert and Response Network (GOARN). Based on experience in the field, partners recognized the need to strengthen operational and technical coordination, and rapid deployment of multidisciplinary multi-agency response teams to support local communities and health authorities.

Over the past 20 year, achievements have been made in responding to major outbreak; and major challenges has been identified. In addition, the global landscape of outbreak response has become more multisectoral, with new regulations, agencies and networks having also been

established. The numbers of partners and stakeholders has increased dramatically and international coordination and funding has become more complex. In all of this, keeping the affected communities at the centre of the response, has not always been easy, or successful.

The COVID-19 pandemic has a devastating impact on health, and on society; and presents unprecedented challenges for countries, international coordination, and solidarity. GOARN partners and technical networks are heavily involved directly in domestic and international response to the COVID-19 pandemic.

This panel debate will bring together representatives of GOARN partners and networks to reflect the highly interconnected multidisciplinary and operational nature of outbreak response.

Most importantly, the panel will discuss the major operational gaps and technical challenges that have been exposed by the pandemic; the steps needed now as our pandemic response evolves, and to accelerate national and global preparedness and rapid response for further emerging disease threats.

For GOARN, this panel will be part of a developing process of review and improvement in technical and operational areas of global pandemic prevention, preparedness, and response, and will help direct how GOARN will contribute to the COVID-19 pandemic response, and to future similar events.

CHAIRS

Dale Andrew Fisher

World Health Organization (WHO) | Global Outbreak Alert and Response Network | Chair

Johanna Hanefeld

London School of Hygiene and Tropical Medicine | Lead LSHTM Berlin and Associate Professor Health Policy and Systems | Germany

SPEAKERS

Omar Abdi

UNICEF | Deputy Executive Director for Programmes

Emanuele Capobianco

International Federation of Red Cross and Red Crescent Societies (IFRC) | Director Health and Care | Switzerland

Xiaoping Dong

Chinese Center for Disease Control and Prevention (China CDC) | Center for Global Public Health | Director | China

Rebecca Martin

Centers for Disease Control and Prevention (CDC) | Center for Global Public Health | Director | United States of America



Omar Abdi

Dale Andrew Fisher

Michael Ryan



Emanuele Capobianco

Johanna Hanefeld

Amadou Sall



Xiaoping Dong

Rebecca Martin

Micaela Serafini

Michael Ryan

World Health Organization Emergencies Programme (WHO) | Executive Director

Amadou Sall

Institut Pasteur de Dakar | Director | Senegal

Micaela Serafini

Médecins Sans Frontières (MSF) | Task Force Leader - Access to COVID-19 Tools | Germany

PD 24

SAAL 10 | ASIA
11:00 – 12:30



SAPIENZA
UNIVERSITÀ DI ROMA

PANEL DISCUSSION

MIGRANT AND REFUGEE HEALTH

Towards an Agenda of Solutions

HOSTS

M8 Alliance

Sapienza University of Rome

Global migration is one of the most compelling human experiences of our time. It has increased as a result of conflict, persecution, environmental degradation and change, and a profound lack of human security and opportunity. The IOM estimates that currently 278 million people (approximately 1 in every 30) are international migrants. Global displacement reported by UNHCR includes nearly 80 million being forced from their homes as a result of persecution, conflict or generalized violence. The number of refugees is estimated currently at more than 26 million, 68% coming from Afghanistan, Myanmar, South Sudan, the Syrian Arab Republic and Venezuela. The UNHCR also has information for 3.9 million stateless people, although there may be many more denied nationality and access to basic rights such

as education, health care, employment and freedom of movement. Refugees and migrants remain among the most vulnerable members of society despite existing and ratified international human rights standards and conventions that protect the rights of refugees and migrants—including their right to health—many lack access to health services and financial protection in health for themselves and their family members. They often suffer from discriminatory migration policies and have limited access to health and social services despite being exposed to many health risks, including exploitation, dangerous working and substandard living conditions.

COVID-19 has shown us that our health system is as strong as our weakest link. Investing in the health of refugees and

migrants is therefore key to not only to controlling and managing the pandemic but addressing the health needs of migrants improves their health and integration and advances global public health and UHC.

In this session, after an update from the European Commissioner for Home Affairs about the recent regulations of the European Union related to immigration, well known experts in the field will present and discuss migrant and refugee health issues in Europe and beyond.

CHAIR

Luciano Saso

Sapienza University of Rome | Faculty of Pharmacy and Medicine |
Vice-Rector for European University Networks |
Italy

SPEAKERS

Ibrahim Abubakar

UCL Institute for Global Health (IGH) |
Director |
United Kingdom

Ylva Johansson

European Commission |
European Commissioner for
Home Affairs |
Belgium

Dominique Kerouedan

Sciences Po Paris |
Concentration in Global Health |
Founder, Lecturer and Scientific Advisor |
France

Akihiro Seita

UNRWA | Health Department |
Director of the Department

Santino Severoni

World Health Organization (WHO) |
Director of Health
and Migration Program



Ibrahim
Abubakar



Luciano
Saso



Ylva
Johansson



Akihiro
Seita



Dominique
Kerouedan



Santino
Severoni

PD 25

SAAL 2 | AMERICA
11:00 – 12:30



PANEL DISCUSSION

WOMEN'S HEALTH IN THE COVID-19 ERA

Can Lessons Learnt from the COVID-19 Crisis Catalyze
a Paradigm Change in Healthcare?

HOSTS

Charité – Universitätsmedizin Berlin

M8 Alliance

Giving primary prevention a key role is one of the main lessons that can already be drawn from the management of the COVID-19 health crisis. High population acceptance of primary prevention measures and high-quality primary care is essential to keep hospital care systems functional and to save lives. Only collective behavior changes can lead to substantial health impact. In analogy to women cancers and NCD in general, primary prevention such as HPV vaccination and screening programs by innovative testing technologies are known to be effective. However, this will reduce hospital care workload only if collective health behavior changes are achieved and high-quality primary care services are accessible for all.

In the post COVID-19 era, hospital care systems will be overwhelmed because of major backlogs in the management of non-COVID-19 related health conditions. This will be most relevant in low- and middle-income countries. It is the right timing to use the momentum of the COVID-19 crisis for a paradigm change in health systems design where primary prevention and innovative primary health care systems will play a prominent role by building upon experiences from the women health agenda.

The mandate given to national governments by the UN General Assembly to develop stepwise universal health coverage is a great challenge and requires an adaptation of health agendas. The post

COVID-19 era is a unique opportunity to increase aid effectiveness by overcoming institutional barriers between the operating health agencies national governments, NGOs, and academia. Innovation in knowledge transfer will

enable the development of a global community of healthcare providers who will lead the necessary changes in primary care level and where women health will spearhead health system changes.

CHAIRS

Jalid Sehoul

Charité – Universitätsmedizin Berlin |
Department of Gynecology |
Medical Director |
Germany

Andreas Ullrich

Charité – Universitätsmedizin Berlin |
Department of Gynecology |
Visiting Scientist |
Germany

SPEAKERS

Teresa Graham

Roche Pharmaceuticals |
Head of Global Product Strategy |
Switzerland

Shannon Hader

Joint United Nations Programme
on HIV and AIDS (UNAIDS) |
Deputy Executive Director

Anja Langenbucher

Gates Foundation |
European Office | Director |
Germany

Princess Nothemba Simelela

World Health Organization (WHO) |
Special Advisor to the Director-General,
Strategic Programmatic Priorities



Teresa
Graham



Jalid
Sehoul



Shannon
Hader



Princess Nothemba
Simelela



Anja
Langenbucher



Andreas
Ullrich

WS 17

SAAL 4 | AFRICA
11:00 – 12:30

vfa Die forschenden
Pharma-Unternehmen
Research-Based
Pharmaceutical Companies



WORKSHOP

FIGHTING FALSIFIED AND SUBSTANDARD MEDICINES DURING THE COVID-19 CRISIS

Increased Demand and Interrupted Supply Chains Offer
Opportunities for Counterfeiters

HOSTS

Association of Research-based Pharmaceutical Companies (vfa)

German Federal Ministry for Economic Affairs and Energy (BMWi)

The fight against falsified and substandard medicines in low- and middle-income countries (LMICs) is a major challenge. With constrained access to essential medicines, weak technical capacity for medicine quality assurance and control, and challenges in appropriate governance both in health care facilities and in national medicines regulatory authorities, many LMICs show the conditions which WHO has identified as favoring the occurrence of substandard and falsified medicines. Additionally, the COVID-19 crisis led to a disruption of the production

and supply chains of medicines worldwide, and some countries stopped the export of medicines. Newly developed medicines and vaccines against COVID-19 will be in very high demand. All this creates increased opportunities for the distribution of falsified medicines by criminals.

In this session we will try to assess the situation from the viewpoints of different stakeholders, and discuss possible strategies to counteract the proliferation of falsified medicines, with a focus on Africa.

CHAIR

Lutz Heide

Eberhard Karls University Tuebingen | Professor of Pharmaceutical Biology | Germany

SPEAKERS

Moji Christianah Adeyeye

National Agency for Food & Drug Administration and Control (NAFDAC) | Director-General | Nigeria

Karim Bendhaou

Merck | Head of Africa Bureau | Germany

Pierre Claver Kayumba

National University of Rwanda | Faculty of Medicine | Senior Lecturer and Researcher | Rwanda

Richard Neci

Ecumenical Pharmaceutical Network (EPN) | Executive Director | Kenya

Sachiko Ozawa

University of North Carolina | Eshelman School of Pharmacy | Associate Professor | United States of America



Moji Christianah Adeyeye



Pierre Claver Kayumba



Karim Bendhaou



Richard Neci



Lutz Heide



Sachiko Ozawa

WS 18

SAAL 5 | OCEANIA
11:00 – 12:30



Federal Ministry
for Economic Cooperation
and Development

WORKSHOP

DEVELOPING STRATEGIES FOR FIGHTING COVID-19 AROUND THE WORLD

(PART 2)

HOST

German Federal Ministry for Economic Cooperation and Development (BMZ)

Even pandemics with global dimensions have local and regional origins. This high-level event under the patronage of the German Federal Ministry for Economic Cooperation and Development (BMZ) and Charité Universitätsmedizin Berlin is therefore intended to gather and exchange international experience from the fight against these kinds of risks. An international and multisectoral expert panel will identify, present and discuss

both technical principles and concrete operational measures from practice. As a result, a range of recommendations for future action will be formulated. Addressing the One Health approach, which especially in the course of the current pandemic, as multisectoral and holistic approach, has gained increasing attention, will be one practical example of the session.

CHAIR

Maria Flachsbarth

Federal Ministry for Economic Cooperation and Development (BMZ) |
Parliamentary State Secretary |
Germany

SPEAKERS

Andrea Ammon

European Centre for Disease Prevention
and Control (ECDC) | Director |
Sweden

Gerd Müller

Federal Ministry for Economic
Cooperation and Development (BMZ) |
Federal Minister for Economic
Cooperation and Development |
Germany

John Nkengasong

Africa Centres for Disease Control
and Prevention | Director |
Ethiopia

Soumya Swaminathan

World Health Organization (WHO) |
Chief Scientist

Elhadj As Sy

Kofi Annan Foundation |
Chair of the Board |
Switzerland



Andrea
Ammon

John
Nkengasong



Maria
Flachsbarth

Soumya
Swaminathan



Gerd
Müller

Elhadj As
Sy

PD 26

Live | SAAL 1
RUDOLF VIRCHOW
Overflow | SAAL 6
EUROPE
13:00 – 13:30

thebmj



UNITED NATIONS
UNIVERSITY

UNU-IIGH
International Institute
for Global Health



**World Health
Organization**

PANEL DISCUSSION

BMJ COLLECTION—WOMEN'S HEALTH AND GENDER INEQUALITIES

Lessons and Emerging Priorities 25 years after the Beijing Platform for Action

HOSTS

The BMJ

UNU International Institute for Global Health (UNU-IIGH)

World Health Organization (WHO)

The 25 years since the visionary Beijing Declaration and Platform for Action for Women have seen dramatic changes globally. While there has been important, albeit chequered, progress on some fronts, new challenges have emerged, including the current COVID-19 pandemic. Demographic, epidemiological, technological and socio-economic transitions have evolved the nature of risks and drivers of women's health, their access to healthcare services, experience of ill health and quality of life. Climate change, migration, and humanitarian crises are precipitating new risk factors. Rapid urbanization, greater economic participation of women and rising socio-economic inequalities coupled with advances in health and medical technologies are affecting women's health and underlying gender inequalities in different ways.

At the same time, the concerns outlined 25 years ago remain deafeningly relevant for women's and girls' health. Millions of women continue to have an unmet need for contraceptives, for example, and adolescent girls still lack sufficient information or quality services to prevent pregnancies, STIs or HIV. This unfinished agenda highlights the lack of real political commitment to women's health and gender equality, as well as the power of the conservative backlash. The COVID-19 pandemic has heightened many of women's health risks, in particular for women healthcare providers, survivors of violence, and women with unintended pregnancies. It has also exacerbated the burden of formal and informal care placed on women and girls. This session will draw on evidence and lessons on advancing women's health since Beijing

to rethink how to better meet their needs, now and in a post-COVID-19 world.

Based on a series of papers commissioned by the British Medical Journal, as part of a joint collection with the United

Nations University and the World Health Organization, panelists will reflect on progress, emerging opportunities, risks, and a forward-looking agenda for women and health towards 2030 and beyond.

CHAIR

Princess Nothemba Simelela

World Health Organization (WHO) |

Special Advisor to the Director-General, Strategic Programmatic Priorities

SPEAKERS

Pascale Allotey

United Nations University |
International Institute for Global Health
(UNU-IIGH) | Director of the Institute |
Malaysia

Claudia Garcia-Moreno

World Health Organization (WHO) |
Department of Sexual and Reproductive
Health and Research | Unit Head

Asha George

University of the Western Cape |
School of Public Health | Professor |
South Africa

Paul Simpson

The British Medical Journal |
International Editor |
United Kingdom

Lavanya Vijayasingham

United Nations University |
International Institute for Global Health |
Postdoctoral fellow |
Malaysia



Pascale
Allotey

Princess Nothemba
Simelela



Claudia
Garcia-Moreno

Paul
Simpson



Asha
George

Lavanya
Vijayasingham

KEY 05

SAAL 1
RUDOLF VIRCHOW
14:00 – 15:30



KEYNOTE

PARTNERSHIP FOR THE GOALS

United Nations 75th Anniversary

HOSTS

German Federal Ministry of Health (BMG)

World Health Organization (WHO)

Achieving the Sustainable Development Goals, our shared vision for the future, will require cooperation across borders, sectors, and generations. Due to COVID-19 we are witnessing a roll back in goal achievement—related to health and to many social determinants and especially for women and children. Now we need collective action and solidarity more than ever, and a clear commitment to global common goods. This is what the United Nations (UN) stands for. New groundbreaking partnerships—such as COVAX and the ACT-Accelerator are being developed and can serve as examples that it can be done.

The UN General Assembly 75 has seen extraordinary commitments expressed by many leaders for SDG achievement and global health. The warnings by the UN Secretary General and the Director-General of the World Health Organization (WHO) on the need to support for global cooperation and multilateralism must be heeded at a time when in many countries public trust in traditional institutions is in decline and human rights are disregarded. As relations between countries come under strain, dialogue and action on global issues—nearly all of which directly and indirectly affect health—could not be more urgent. How do we support the UN in its aim to build a global vision of 2045 (its centenary) and support enhanced international cooperation to realize that vision.

CHAIR

Bernhard Schwartländer
World Health Organization (WHO) | Chief of Staff

SPEAKERS

Inger Ashing
Save the Children International | CEO |
United Kingdom

Michelle Bachelet
United Nations |
High Commissioner for Human Rights

Seth Berkley
Gavi, the Vaccine Alliance | CEO |
Switzerland

Rafael Mariano Grossi
International Atomic Energy Agency |
Director-General

Natalia Kanem
United Nations Population Fund
(UNFPA) | Executive Director



Inger
Ashing

Rafael Mariano
Grossi



Michelle
Bachelet

Natalia
Kanem



Seth
Berkley

Bernhard
Schwartländer

PD 27

SAAL 6 | EUROPE
14:00 – 15:30

PANEL DISCUSSION

DIGITAL HEALTH & AI
FOR PANDEMIC PREPAREDNESS

United Nations A Post Novel Coronavirus Pneumonia (COVID-19)
and Chronic Non-Communicable Disease (NCD) Pandemic Framework
for Global Action in the Digital Economy & Society 2030

HOST

Global He@lth 2030 Innovation Task Force

Digital Health and Artificial Intelligence (AI) are the future of health protection, delivery and emergency management. Like HIV/AIDS in 2000 and the Ebola and Zika outbreaks in 2014 and 2016, the novel coronavirus pneumonia (COVID-19) pandemic is a defining moment in global health security leadership. Marshalling a concerted global and regional effort for risk, resilience, response, reconstruction and recovery must this time include full multi-stakeholder engagement as essential to pandemic preparedness in the digital era. This will extend to future essential innovative funding mechanisms, R&D networks and Centers of Excellence. China's COVID-19 response employed a strengthened national health system after the SARS 2003 and H1N1 2009 outbreaks, and widespread use of ubiquitous mobile and digital health and finance technologies in government and business partnership.

All lack global standardization today, and COVID-19 has shockingly laid bare the fragmentation and chronic under-funding of national health systems across the world. Employing winning strategies with amplified ambition needs to be defined and disseminated for shared use at scale in the current planetary pandemic and beyond. COVID-19 is much more than a wake-up call for systemic and sustainable digital health ecosystem transformation. It has cruelly exposed the chasm in mind-sets and modalities between not only the global health and financial communities, but also between global technology and pharmaceuticals industries. WHO, UN Member States, civil society and the private sector must radically rethink their anemic and anachronistic stratagems for pandemic preparedness, UHC 2030 and Chronic NCDs in the Digital Economy & Society of the 21st Century.

CHAIR

Denis Gilhooly
Global He@lth 2030 Innovation Task Force | CEO | United States of America

SPEAKERS

George F. Gao
Chinese Center for Disease Control
and Prevention | Director |
China

Florence Gaudry-Perkins
Digital Health Partnerships (DHP) |
Founder & CEO |
France

Joann O'Brien
TM Forum | Digital Ecosystems |
Vice President |
United States of America

Bernd Ohnesorge
Siemens Healthineers AG |
President EMEA |
Germany

Soumya Swaminathan
World Health Organization (WHO) |
Chief Scientist



George F.
Gao



Joann
O'Brien



Florence
Gaudry-Perkins



Bernd
Ohnesorge



Denis
Gilhooly



Soumya
Swaminathan

WS 19

SAAL 4 | AFRICA
14:00 – 15:30



WORKSHOP

A EUROPEAN UNION IN HEALTH

Role of a European Council for Health Research

HOSTS

Charité – Universitätsmedizin Berlin

M8 Alliance

In the wake of COVID-19, the need for concerted action for health in Europe led the European Commission to propose an ambitious program for health for 2021–2028. There is little doubt that to address the needs in health, whether pandemic preparedness, chronic disease, child health or environment, global and multi-sectoral collaboration is necessary.

MEPs and major organizations have called for European leadership in health, addressing inequity in Europe and bridging health, research and innovation. A European Council for Health Research as a multi-stakeholder platform could be a first step. Panel members will discuss potential scenarios on the road to a European Health Union.

CHAIRS**Laurent Degos**

French Academy of Science |
Corresponding Member |
France

Karin R. Sipido

KU Leuven | Professor of Medicine and
Head of Experimental Cardiology |
Belgium

SPEAKERS**Christian Drosten**

Charité – Universitätsmedizin Berlin |
Institute of Virology Campus Charité
Mitte | Director of the Institute |
Germany

Hans Hofstraat

Philips Research |
Vice President Research |
The Netherlands

Susanna Palkonen

EFA – European Federation of
Allergy and Airways Diseases Patients'
Associations | Director |
Belgium

John-Arne Røttingen

Chief Executive |
Research Council |
Norway



Laurent
Degos



Hans
Hofstraat



Christian
Drosten



Karin R.
Sipido

WS 20

SAAL 5 | OCEANIA
14:00 – 15:30



WORKSHOP

NEW VOICES IN GLOBAL HEALTH

Perspectives and Responses of Young Scientists to the Coronavirus Pandemic

HOST

Global Young Academy (GYA)

Members of Young Academies and similar early to mid-career scientist networks share their perspectives and responses to the coronavirus pandemic. Speakers will give a concise input in the format of a lightning talk. Each lightning

talk will provide a defined input to create a common basis for discussion, which will be a key element of the session to hear New Voices in Global Health among the audience and speakers.

CHAIRS

Stefan Kohler

Global Young Academy |
Co-lead, Global Health
Working Group | Germany

Wibool Piyawattanametha

Global Young Academy |
Alumnus | Thailand

SPEAKERS

Monir Ahmed

Global Young Academy |
Qassim University |
Department of Medical Labora-
tories | Assistant Professor |
Saudi Arabia

Shymaa Enany

Egyptian Young Academy
of Sciences |
Suez Canal University |
Department of Microbiology
and Immunology |
Associate Professor |
Egypt

Sri Fatmawati

Indonesian Young Academy
of Sciences |
Institut Teknologi Sepuluh
Nopember | Department of
Chemistry | Lecturer |
Indonesia

Arya Shalini Subash

Global Young Academy |
Executive Committee Member |
India

Abul Bashar Mir Md Khademul Islam

National Young Academy
of Bangladesh |
University of Dhaka | Department
of Genetic Engineering and Bio-
technology | Associate Professor |
Bangladesh

Paramdeep Singh

Indian National Young Academy
of Science |
Baba Farid University of Health
Sciences | Department of Radiology |
Associate Professor | India

Daniel De Jesus Limonta Velazquez

Global Young Academy & Academy
of Sciences for the Developing
World Young Affiliate Alumnus |
University of Alberta |
Department of Cell Biology |
Postdoctoral Fellow |
Canada



Monir
Ahmed



Abul Bashar Mir Md
Khademul Islam



Paramdeep
Singh



Shymaa
Enany



Stefan
Kohler



Arya Shalini
Subash



Sri
Fatmawati



Wibool
Piyawattanametha



Daniel De Jesus
Limonta Velazquez

KEY 06

SAAL 1
RUDOLF VIRCHOW
16:00 – 17:30



Federal Ministry
of Health



World Health
Organization

KEYNOTE

ACCELERATING THE SDG 3 GLOBAL ACTION PLAN FOR HEALTH AND WELL-BEING

HOSTS

German Federal Ministry of Health (BMG)

World Health Organization (WHO)

The Global Action Plan for Healthy Lives and Well-Being for All brings together 12 multilateral health, development, and humanitarian agencies to better support countries and accelerate progress towards health-related Sustainable Development Goals. Under the Global Action Plan, the agencies are better aligning their work to reduce inefficiencies and provide more streamlined

support to countries and forums for international commitments to health, such as the UN High-Level Meeting on Universal Health Coverage and the Astana Conference on Primary Health Care. At the World Health Summit, representatives of the signatory agencies will present updates on the Action Plan, and its challenges and successes.

CHAIR

Ilona Kickbusch
The Graduate Institute of International and Development Studies |
Global Health Center | Chair of the International Advisory Board |
Switzerland

SPEAKERS

Tedros Adhanom Ghebreyesus
World Health Organization (WHO) |
Director-General

Jeremy Farrar
Wellcome Trust | Director |
United Kingdom

Henrietta H. Fore
United Nations Children’s Fund (UNICEF) |
Executive Director

Muhammad Pate
Global Financing Facility (GFF) |
Director |
United States of America

Peter Sands
The Global Fund to Fight AIDS,
Tuberculosis and Malaria |
Executive Director |
Switzerland

Marisol Touraine
Unitaid | Chair of the Executive Board



Tedros Adhanom
Ghebreyesus



Muhammad
Pate



Jeremy
Farrar



Peter
Sands



Henrietta H.
Fore



Marisol
Touraine



Ilona
Kickbusch

GENERAL INFORMATION

ACCESS TO THE VENUE

Participants and speakers must present a valid photo ID to pick up their badges. Please be advised that bags may be inspected for security reasons. We kindly ask that you refrain from bringing luggage to the venue. Badges should be worn at all times, and are required to enter all sessions.

Please note: Due to COVID-19 only a limited number of participants is permitted at the venue and in the session rooms. All sessions will be broadcast online; the links are available in the program.

CAPACITY LIMITS

Due to the pandemic-induced regulations regarding distancing and hygiene, the capacity of session rooms and the venue as a whole is limited. The organizers reserve the right to refuse access to the venue or to session rooms if the maximum capacity has been reached. We follow the “first come—first served” principle throughout the conference and in all sessions.

CATERING

Food and beverage distribution during break times follows the COVID-19 hygiene guidelines.

CLOAKROOM

The cloakroom is located to the left of the entrance and is free of charge.

COVID-19 REGULATIONS

The organizers comply with all official stipulations, implement necessary measures, and follow all rules regarding hygiene, protective gear, distancing, number of participants, etc.

- Hygiene: Disinfectants are available throughout the venue
- Distance: At least 1,50 meter between individual participants in seating
- Masks: It is mandatory to wear a mouth and nose protection in the entire venue and at all times.

DIGITAL PARTICIPATION

You are cordially invited to take part in the World Health Summit 2020 digitally:

All sessions will be broadcast online with Q&A opportunities for all digital participants.

- Access is possible worldwide via PC, tablet, smartphone
- High reliability through load-balancing features for low-bandwidth situations
- Interactive formats through Q&A function, screen, and document sharing
- One proper entry link per session available in the program:
www.conference.worldhealthsummit.org/Program/WHS2020

EMERGENCY NUMBERS (Germany)

Ambulance/Fire: 112
Police: 110

INTERNET

WiFi is available throughout the venue.

Network: WorldHealthSummit
Password: #WHS2020

MEDIA

The World Health Summit is fully open to the press, but due to COVID-19, places for journalists on-site are limited. Press badges are available at the media desk at the entrance of the venue. Please present a valid photo ID. The press badge must be worn at all times during the World Health Summit.

End of Accreditation for on-site participation: Wednesday, Oct. 21:
www.worldhealthsummit.org/media/accreditation.html

Digital participation is possible without accreditation via:
www.worldhealthsummit.org or
www.conference.worldhealthsummit.org/Program/WHS2020.

Press information:
www.worldhealthsummit.org/media/presskit.html

Press contact:
communications@worldhealthsummit.org

LOST AND FOUND

Lost items can be collected at the registration counter during the World Health Summit. After the summit, unclaimed items will be held by the venue for a limited time only.

PARKING

Parking is available at the venue in an underground lot.

PEOPLE WITH DISABILITIES

The venue is accessible to participants with disabilities. If you require specific accommodations, please inform summit staff:
contact@worldhealthsummit.org

PROGRAM CHANGES

The program is subject to changes due to unforeseen circumstances. Please check the interactive online program planner on our website for regular updates.
www.conference.worldhealthsummit.org/Program/WHS2020

REGISTRATION

The registration desk is open during the following times:

Sunday, October 25	9:00 – 17:30
Monday, October 26	8:00 – 18:00
Tuesday, October 27	8:00 – 18:00

SOCIAL MEDIA

#WHS2020

Follow us on

 www.twitter.com/worldhealthsmt
 www.facebook.com/worldhealthsummit
 www.linkedin.com/company/worldhealthsummit
 www.youtube.com/user/WorldHealthSummit1

SPEAKER CENTER

The speaker center is located on the upper level. Speakers must bring any audio-visual materials they require to the speaker center prior to their session.

Presentations cannot be run from personal laptop computers in the session rooms.

The speaker center is open during the following times:

Sunday, October 25	10:00 – 18:00
Monday, October 26	8:00 – 18:00
Tuesday, October 27	8:00 – 18:00

TAXI

Taxi Berlin	+49 30 202020
Taxi Würfelfunk	+49 30 210101
Taxi Funk	+49 30 443322

BERLIN HEALTH EXCELLENCE— EXPERTISE AND CUTTING-EDGE MEDICINE MADE IN BERLIN

Berlin's success as a health capital reflects a 300-year tradition as a healthcare and scientific centre. More than a dozen Nobel Prize winners worked here, including researchers such as Rudolf Virchow and Robert Koch. One of Berlin's most famous medical institutions is the renowned Charité, Europe's largest university hospital and one of Germany's leading hospitals. World-renowned scientists of the Charité cooperate closely with recognised research organisations such as the Massachusetts Institute of Technology in Boston. The Berlin Institute of Health is an important third pillar alongside health care and the medical faculty. The aim is to transfer the research results from the laboratory to clinical care as quickly as possible and thus to provide patients in Berlin with the best possible care.

Other outstanding hospitals are the German Heart Centre—a top-level hospital for heart and vascular diseases under the leadership of world famous heart surgeon Professor Dr. med. Volkmär Falk, or Vivantes—with its nine clinics and several rehabilitation centres being Germany's largest municipal hospital group.



Humboldtforum



Delphi-Saal

Many more hospitals and doctor's surgeries could be mentioned, as all of them offer top-class medical treatment and provide medical experts of all disciplines.

Medical care at the highest level requires a strong collaboration between scientists and practitioners. Berlin is a leading centre of science and research in Europe, especially focusing on medicine. Four public universities, the Charité teaching hospital, seven universities of applied sciences and over 30 private universities offer teaching and research facilities for people from all over the world. Germany's most important research organizations such as the Fraunhofer-Gesellschaft or the Max Planck Society are represented in Berlin, and successful technology parks like the tech-hub Adlershof or biotech park Campus Berlin-Buch are established here.

More information at
www.berlin-health-excellence.com

For the latest information,
see www.visitBerlin.com

BERLIN— CAPITAL OF CULTURE

Apart from the excellent quality of medical services in Berlin, the city's many green spaces, parks and leisure amenities offer high-quality relaxation to support a patients' recovery. The German capital is also well known for its diversity of cultural events and venues.

Berlin's museums and galleries offer everything, from ancient art to world-class old masters and avant-garde design, from classical opera to musicals and pop concerts. Culture and art enthusiasts can admire outstanding works from down the centuries to today's cutting-edge art styles. The five museums on the Museum Island in the historic city centre are home to world-renowned collections. Here, you can admire exceptional treasures and artefacts from 3,000 years of human history—for example, in the Neues Museum with the famous bust of Nefertiti. In contrast, the nearby Martin-Gropius-Bau presents contemporary art.

Berlin is one of the world's few cities to have three opera houses: Classical music lovers can choose from a repertoire of famous works or new and experimental operas. Apart from these opera houses, the city's eight large orchestras, including the world-famous Berliner Philharmoniker conducted by Kirill Petrenko, also make for high-class musical enjoyment.

This year Berlin marked a very special centenary. In 1920, modern Berlin was created more or less overnight. Formed from eight towns and numerous local authorities, Greater Berlin became the world's second largest metropolitan city after New York. In 2020, Berlin has



held various exhibitions to celebrate this centenary, including *Chaos & Renewal—Berlin 1920/2020* in the Märkisches Museum and *100 Years of (Greater) Berlin: An Uncompleted Project* in the Kronprinzenpalais. These exhibitions not only showcase the historical event, but create an arc to present-day Berlin and present visions of the future city.

In December this year, the new Humboldt Forum in the reconstructed Berlin Palace is opening its first sections to the public, including an exhibition on the history of the site and the Schlosspassage with the museum shop. The Asian Art Museum and the Ethnological Collections are scheduled to open in 2021. Not only will the new Humboldt Forum then be showing world-class cultural works, but this will also complete Berlin Mitte, the cultural heart of the city.

During the corona pandemic, the health of Berlin's guests is a top priority. Museums, concert halls and opera houses as well as meeting venues have all developed comprehensive and detailed hygiene concepts. Thanks to time slot tickets bookable online and the generous spaces in these venues, guests can enjoy a relaxed cultural experience.

PRESIDENTS

2020



CHARLES IBINGIRA
 International President
 2020 & 2021
 Principal
 Makerere University
 College of Health Sciences,
 Uganda



DETLEV GANTEN
 Founding President
 World Health Summit
 Charité – Universitäts-
 medizin Berlin
 Germany

SCIENTIFIC COMMITTEE

The World Health Summit Scientific Committee consists of the M8 Alliance Executive Committee (see page 140) and selected members of the World Health Summit Council.

MEMBERS



TILL BÄRNIGHAUSEN
 Director
 Heidelberg Institute
 of Global Health,
 Germany

CO-CHAIRS



STEFAN KAUFMANN
 Director Emeritus
 Max Planck Institute
 for Infection Biology,
 Germany



DETLEV GANTEN
 President
 World Health Summit,
 Germany



CARLOS SANTOS
 Chairman of the Board
 of Directors
 Coimbra University
 Hospital Center,
 Portugal



THOMAS METTENLEITER
 President
 Institute of Molecular
 Virology and Cell Biology,
 Friedrich-Loeffler-Institut,
 Germany



ELIZABETH BLACKBURN
Nobel Prize Laureate 2009,
President Emerita
Salk Institute
for Biological Studies,
USA



BEN CANNY
Former Head
School of Medicine,
University of Tasmania,
Australia



THOMAS B. CUENI
Director General
International Federation
of Pharmaceutical Manu-
facturers & Associations
(IFPMA), Switzerland



CHRISTIAN DROSTEN
Director
Institute of Virology,
Charité-Universitäts-
medizin Berlin,
Germany



**TARCÍSIO ELOY PESSOA
DE BARROS FILHO**
Dean
Faculty of Medicine,
University of São Paulo,
Brazil



EUGENIO GAUDIO
Rector
Sapienza University
of Rome,
Italy



CHARLES IBINGIRA
Principal
Makerere University
College of Health Sciences,
Uganda



ALI JAFARIAN
Former Chancellor
Tehran University
of Medical Sciences,
Iran



MICHAEL J. KLAG
Former Dean
Johns Hopkins Bloomberg
School of Public Health,
USA



BÄRBEL-MARIA KURTH
Director
Epidemiology and
Health Monitoring,
Robert Koch Institute,
Germany



AXEL RADLACH PRIES
Dean
Charité-Universitäts-
medizin Berlin,
Germany



MAIKE SANDER
Director
Pediatric Diabetes Research
Center, UC San Diego,
USA



GÜNTER STOCK
President
ALLEA -
All European Academies,
Germany

COUNCIL

CO-CHAIRS



ILONA KICKBUSCH
International Advisory
Board Chair
Global Health Centre,
Graduate Institute
Geneva, Switzerland



ELHADJ AS SY
Chair
Kofi Annan Foundation,
Switzerland

MEMBERS

ALA ALWAN
University of Washington,
Department of Global Health

RIFAT ATUN
Harvard T.H. Chan School
of Public Health

TILL BÄRNIGHAUSEN
Heidelberg University

GUNTHER BEGER
German Federal Ministry
for Economic Cooperation
and Development

INGO BEHNEL
German Federal Ministry
of Health

CHRISTOPH BEIER
Deutsche Gesellschaft für
Internationale Zusammenarbeit

CHRISTOPH BENN
Director Global Health
Diplomacy, The Joep Lange
Institute

TOBIAS BERGNER
German Federal Foreign Office

ARNAUD BERNAERT
World Economic Forum

CATHERINA BÖHME
Foundation for Innovative New
Diagnostics

THOMAS B. CUENI
Int. Federation of Pharma-
ceutical Manufacturers &
Associations (IFPMA)

MANFRED DIETEL
Charité – Universitätsmedizin
Berlin

KLAUS DUGI
Ferring Pharmaceuticals

TIMOTHY EVANS
World Bank

ROLAND GÖHDE
GHA – German Health Alliance

JÖRG HACKER
German National Academy
of Sciences Leopoldina
(until 2020)

SHANNON HADER
UNAIDS

ANDREW HAINES
London School of Hygiene &
Tropical Medicine

ALEXANDER HEWER
Klinikum Stuttgart

ZSUZSANNA JAKAB
World Health Organization

ASHISH JHA
Brown University

STEFAN KAUFMANN
Max Planck Institute
for Infection Biology

SUSANNA KRÜGER
Save the Children Germany

BÄRBEL KURTH
Robert Koch Institute

STEVE LANDRY
Bill & Melinda Gates Foundation

YVES LEVY
French Institute of Health
and Medical Research Inserm
(until 2018)

MARION LIESER
Oxfam Germany

KLAUS LINDPAINTNER
InterVenn Biosciences

JÜRGEN MLYNEK
Falling Walls Foundation

MATSHIDISO REBECCA MOETI
World Health Organization

BERND MONTAG
Siemens Healthineers

ANDREAS PENK
Pfizer Germany

HAGEN PFUNDNER
Roche Pharma AG

PETER PIOT
London School of Hygiene
and Tropical Medicine

ERICH REINHARDT
Medical Valley

AMBASSADORS

HEINZ RIEDERER

iNG innovation. Nachhaltigkeit.
Gesundheit

MAIKE RÖTTGER

Association Development and
Humanitarian Aid

MATTHIAS SCHELLER

Albertinen-Diakoniewerk

HANS J. SCHELLNHUBER

Potsdam Institute for
Climate Impact Research
(until 2018)

GÜNTER STOCK

ALLEA – All European
Academies

VERONIKA VON MESSLING

German Federal Ministry
of Education and Research

LOTHAR WIELER

Robert Koch Institute



EDELGARD BULMAHN

Former Federal Minister
of Education and Research
Germany



MANFRED DIETEL

Former Director
Institute of Pathology,
Charité – Universitäts-
medizin Berlin,
Germany



ECKART VON HIRSCHHAUSEN

Physician,
TV Host, Comedian
Germany



MICHAEL RABROW

Senior Advisor
E&P Focus Africa
Consulting,
Germany



HEINZ RIEDERER

Managing Director
iNG innovation.
Nachhaltigkeit.
Gesundheit,
Germany



REINHARD SCHÄFERS

Former Ambassador
Federal Republic
of Germany



ANSGAR TIETMEYER

Former Head
of Public Affairs
Deutsche Bank AG,
Germany



CHARLES YANKAH

Chairman
Afrika Kulturinstitut e.V.,
Berlin, Germany

EXECUTIVE COMMITTEE



CHARLES IBINGIRA
International President
2020 & 2021
Principal
Makerere University
College of Health Sciences,
Uganda



DETLEV GANTEN
Founding President
World Health Summit
Charité – Universitäts-
medizin Berlin,
Germany



EUGENIO GAUDIO
International President 2022
Rector
Sapienza University of Rome,
Italy



AXEL RADLACH PRIES
Dean
Charité – Universitäts-
medizin Berlin,
Germany



MICHAEL J. KLAG
Former Dean
Johns Hopkins Bloomberg
School of Public Health,
USA



BEN CANNY
Former Head
School of Medicine,
University of Tasmania,
Australia



ALI JAFARIAN
Former Chancellor
Tehran University
of Medical Sciences,
Iran



**TARCÍSIO ELOY PESSOA
DE BARROS FILHO**
Dean
Faculty of Medicine,
University of Sao Paulo,
Brazil

M8 ALLIANCE HEADS OF DELEGATION

Australia

CHRISTINA MITCHELL
Dean
Monash University, Melbourne

Brazil

TARCÍSIO ELOY PESSOA DE BARROS FILHO
Dean
Faculty of Medicine, University of Sao Paulo

EDUARDO KRIEGER
Former President
Brazilian Academy of Sciences

Canada

PATRICK COSSETTE
Dean
Faculty of Medicine, University of Montreal

MAX FEHLMANN
President and Scientific Director
Montreal Clinical Research Institute

China

XUETAO CAO
President
Chinese Academy of Medical Sciences & Peking Union Medical College

DEPEI LIU
Co-Chair
InterAcademy Partnership (IAP)

France

GÉRARD FRIEDLANDER
Dean
Faculty of Medicine, University of Paris Descartes

FRANÇOIS HOULLIER
Acting President
Université Sorbonne Paris Cité

Germany

HEYO KROEMER
Chief Executive Officer
Charité – Universitätsmedizin Berlin

AXEL RADLACH PRIES
Dean
Charité – Universitätsmedizin Berlin

Iran

ALI JAFARIAN
Former Chancellor
Tehran University of Medical Sciences

AMIRHOSSEIN TAKIAN
Chair
Department of Global Health and Public Policy, Tehran University of Medical Sciences

Italy

EUGENIO GAUDIO
Rector
Sapienza University of Rome

LUCIANO SASO
Vice-Rector for European University Networks
Sapienza University

Japan

SHUNICHI FUKUHARA
Former Dean
School of Public Health, Kyoto University

Portugal

AMÍLCAR FALCÃO
Rector
University of Coimbra

DUARTE NUNO VIEIRA
Dean
Faculty of Medicine, University of Coimbra

Russian Federation

IVAN DEDOV
President
Russian Academy of Medical Sciences

EVGENY SIDORENKO
Vice-President
Russian Academy of Medical Sciences

Singapore

JOHN EU-LI WONG
Chief Executive Officer
National University Health System

KHAY GUAN YEOH
Dean
Yong Loo Lin School of Medicine, National University of Singapore

TEO YIK YING
Vice-Dean (Research)
Saw Swee Hock School of Public Health
National University of Singapore

Switzerland

ANTOINE FLAHAULT

Director
Institute of Global Health

CEM GABAY

Dean
Faculty of Medicine, University of Geneva

BERTRAND LEVRAT

Chief Executive Officer
Geneva University Hospitals

VINH-KIM NGUYEN

Director
Global Health Center,
The Graduate Institute Geneva

NICOLE ROSSET

Deputy Director
Geneva University Hospitals (HUG),
External Affairs and Executive
Management Member

Taiwan

CHANG-CHUAN CHAN

Associate Dean
National Taiwan University

Turkey

MAHMUT AK

Rector
Istanbul University

BAHAÜDDIN ÇOLAKOĞLU

Dean
Istanbul University, Faculty of Medicine

Uganda

CHARLES IBINGIRA

Principal
Makerere University
College of Health Sciences

United Kingdom

DEBORAH ASHBY

Director of the School of Public Health
Imperial College London

PETER PIOT

Director
London School of Hygiene &
Tropical Medicine

USA

ADNAN HYDER

Senior Associate Dean for Research
Milken Institute School of Public Health
at George Washington University

MICHAEL J. KLAG

Former Dean
Johns Hopkins Bloomberg
School of Public Health, Baltimore

ELLEN MACKENZIE

Dean
Johns Hopkins Bloomberg
School of Public Health, Baltimore

International Associations

STEVEN L. KANTER

President & CEO
Association of Academic Health Centers
(AAHC)

ANN KURTH

Chair
Consortium of Universities for Global Health
(CUGH)

LEONEL VALDIVIA

President
World Federation of Academic
Institutions for Global Health (WFAIGH)

Individual Members

RIFAT ATUN

Director
Global Health Systems Cluster,
Harvard T.H.Chan School of Public Health,
USA

BEN CANNY

Former Head
School of Medicine, University of Tasmania,
Australia

A

Abdi, Omar 109
 Abdullah, Khairul 75
 Abubakar, Ibrahim 111
 Addo, Marylyn 85
 Adewara, Funmi 93
 Adeyeye, Moji Christianah 115
 Adomakoh, Nicholas 23
 Aerts, Ann 105
 Agbega, Christopher 93
 Agyeman-Manu, Kwaku 101
 Ahmed, Monir 127
 Ali, Hera 77
 Allotey, Pascale 119
 Ammon, Andrea 31, 41, 117
 Amuasi, John 65, 85, 89
 Annen, Niels 59
 Ashing, Inger 121
 Asiedu-Bekoe, Franklin 27
 Ayakaka, Irene 83
 Azadzoy, Hila 45

B

Bachelet, Michelle 121
 Balaji, Lakshmi Narasimhan 37
 Balasegaram, Manica 23
 Baptista Leite, Ricardo 21, 45, 93
 Baum, Christopher 39
 Bendhaou, Karim 115
 Berankytė, Ieva 77
 Berkley, Seth 121
 Bethell of Romford, Lord 87
 Beyer, Peter 25
 Bhola, Mukul 61

Blohmer, Martin 77
 Bloom, Theodora 39
 Boehme, Catharina 29, 49, 79
 Bonefeld-Dahl, Cecilia 69
 Bönig, Constanze 83
 Brakhage, Axel 73
 Brooks, Steve 25
 Bruchhausen, Walter 63
 Bulmahn, Edelgard 95
 Buyx, Alena 21
 Byanyima, Winnie 45, 51

C

Caleffi, Maira 69
 Campbell, Jim 33
 Campe, Sabine 29
 Capobianco, Emanuele 109
 Capon, Tony 89
 Chan, Chang-Chuan 57
 Chan, Margaret 57, 99
 Charmeil, Olivier 41
 Chataway, Mark 41
 Chopra, Supriya 81
 Cocero, Nanette 51
 Collins, Sir Rory Edwards 105
 Colombo, Francesca 21, 47, 87, 99
 Cooke, Graham 103
 Costa, Alex 23
 Cubelo, Floro 33
 Cueni, Thomas 79, 87

D

Dalil, Suraya 101
 Davies, Dame Sally 25, 55
 Debré, Patrice 49
 Degos, Laurent 125
 De Paula, Nicole 77
 de Szolnok, Jean Scheftsik 65
 de Witte, Bart 21
 Dhatt, Roopa 99
 Dirnagl, Ulrich 21, 39
 Dong, Xiaoping 109
 Doole, Claire 23
 Doyle, Yvonne 71
 Draghia-Akli, Ruxandra 43
 Drosten, Christian 71, 79, 107, 125
 Dzau, Victor J. 43

E

Ehlers, Stefan 85
 Elfadil, H.E. Amira Elfadil Mohammed 61
 Eloit, Monique 107
 El Omrani, Omnia 77
 Enany, Shymaa 77, 127

F

Farrar, Jeremy 129
 Fatmawati, Sri 127
 Fears, Robin 75
 Fisher, Dale Andrew 109
 Fitchet, Martin 57
 Flachsbarth, Maria 65, 107, 117

Fore, Henrietta H. 129
 Forland, Frode 71
 Foster, Juliette 61
 Frieden, Tom 79
 Frohloff, Astrid 87

G

Gabrysch, Sabine 59, 89
 Gantar, Tomaz 67
 Ganten, Detlev 47, 51
 Gao, George F. 31, 123
 Garcia-Moreno, Claudia 119
 Garms, Thomas 25
 Gastmeier, Petra 73
 Gaudry-Perkins, Florence 123
 George, Asha 119
 Gerhardt, Holger 105
 Germann, Stefan 35
 Ghebreyesus, Tedros Adhanom 51, 55, 129
 Ghosh, Shiulie 69
 Gilhooly, Denis 123
 Gill, Amandeep Singh 55
 Göhde, Roland 45
 Goldacre, Ben 39
 Gore, Charles 103
 Gostin, Lawrence O. 35
 Graham, Teresa 69, 113
 Grossi, Rafael Mariano 81, 121
 Guterres, António 51

H

Hader, Shannon 113
 Haines, Sir Andrew 59,75
 Hanefeld, Johanna 63,109
 Harrison, Jim 91
 Hatchett, Richard 43
 Haug, Gerald 89
 Heide, Lutz 115
 Heyder, Ralf 49
 Hillware, Sarah 99
 Hofstraat, Hans 125
 Hörauf, Achim 63,83
 Htwe, H.E. Myint 61
 Hudson, Paul 51
 Huxley, Rachel 59
 Hyder, Adnan A. 57

I

Ibbotson, Geoffrey 91
 Ibingira, Charles 51
 Iro, Elizabeth 33
 Islam, Abul Bashar Mir Md
 Khademul 127
 Iyer, Jayasree K. 29,79,103

J

Jafarian, Ali 91
 Janušonytė, Eglė 77
 Jinks, Tim 87
 Johansson, Ylva 111

K

Kanem, Natalia 121
 Katuta, Hon. Given 45

Kaufmann, Stefan H.E. 43,85
 Kayumba, Pierre Claver 115
 Kennedy, Annette 33
 Kerouedan, Dominique 111
 Kickbusch, Ilona 31,67,129
 Kieny, Marie-Paule 37
 Kinnair, Dame Donna 33
 Klapper, Bernadette 37
 Köhler, Carsten 83
 Kohler, Stefan 127
 Krause, Gérard 27
 Kurzai, Oliver 73
 Kyriakides, Stella 55

L

Langenbucher, Anja 113
 Larsson, Joakim 25
 Leitner, Carl 27
 Liu, Depei 43
 Lodunu-Senoo, Cecilia 101
 Logora, Makoy Yibi 83
 Lucchini, Marc-Antoine 93

M

Malecela, Mwelecele Ntuli 83
 Mariano Jr., Bernardo 35,55
 Martin, Rebecca 109
 Mattar, Caline 77
 McNeill, Jeremy 75
 Meara, John G. 91
 Mehnert, Anja 69
 Ménard, Joël 105
 Mestres, Isabel 69

Mettenleiter, Thomas C.
 73,107
 Mikkelsen, Bente 61,93
 Miller, Jeni 59
 Miribel, Benoît 47
 Mohammed, Bello Abubakar
 81
 Montag, Bernd 35
 Monti, Roberto Francesco
 95
 Muhsin, Muhsinzoda Gafur
 101
 Müller, Gerd 107,117
 Müller, Jürgen 41
 Mundani, Dagmar 21
 Mundel, Trevor 43
 Murenga, Maurine 103

N

Neci, Richard 115
 Neumaier, Michael 21
 Ngamiye, H.E. Daniel 61
 Nimmesgern, Elmar 23
 Nkengasong, John 31,117
 Nobre, Carlos A. 59
 Nsiah-Asare, Anthony 65
 Nur, Fawziya Abikar 101
 Nurse, Joanna 57

O

Obiero, Christina 23
 O'Brien, Joann 123
 Oelrich, Stefan 87

Ohnesorge, Bernd 123
 Oni, Tolullah 37,95
 Ozawa, Sachiko 115

P

Palkonen, Susanna 125
 Pate, Muhammad 129
 Pickel, Birgit 63
 Piot, Peter 79
 Piyawattanametha,
 Wibool 127
 Portella, Gina 105
 Pulcini, Céline 25

R

Rehfuess, Eva 71
 Reis, Andreas Alois 39
 Reitenbach, Dagmar 23
 Renshaw, Nina 93
 Reynolds, Teri 91
 Roche, Benjamin 89
 Røttingen, John-Arne 125
 Rupp, Jochen 49
 Ryan, Michael 109

S

Sabino, Ester Cedeira 99
 Safi, Malik Muhammad 101
 Sall, Amadou 109
 Samad, Lubna 91
 Samiya, Aishath 55
 Sands, Peter 129
 Santos, Clara Cruz 95

Saso, Luciano 111
 Schmid, Peter 73
 Schmitt, Tugce 77
 Schmutte, Caroline 63
 Schwartländer, Bernhard 67,121
 Seeberger, Peter H. 49
 Sehouli, Jalid 113
 Seita, Akihiro 111
 Serafini, Micaela 109
 Severoni, Santino 111
 Seydoux, Stéphanie 31
 Shah, Rajiv 55
 Shaikh, Mujahed 37
 Sillanaukee, Päivi 35
 Simão, Mariângela 103
 Simelela, Princess Nothemba 113,119
 Simón, Fernando 71
 Simpson, Paul 119
 Singh, Paramdeep 127
 Sinkins, Steven 85
 Sipido, Karin R. 125
 Sliwa-Hahnle, Karen 105
 Snower, Dennis J. 47
 Sørensen, Kristin 37
 Soucat, Agnès 47
 Spahn, Jens 67
 Starke, Dagmar 27
 Steinmeier, Frank-Walter 51
 Stoffels, Paul 29
 Stoltenberg, Camilla 65
 Strech, Daniel 39

Streeck, Hendrik 45
 Subash, Arya Shalini 127
 Sunder, Wolfgang 73
 Swaminathan, Soumya 43,55,71,117,123
 Sy, Elhadj As 99,117
 Szlamka, Zsófia 77

T

Takian, Amirhossein 57
 Tanden, Neera 95
 Temido, Marta 67
 ter Meulen, Volker 75
 Torode, Julie 81
 Touraine, Marisol 103,129

U

Ullmann, Andrew 45
 Ullrich, Andreas 113

V

Vaïsse, Justin 95
 Vayena, Effy 35
 Vehviläinen-Julkunen, Katri 33
 Velaphi, Sithembiso 23
 Velazquez, Daniel De Jesus Limonta 127
 Vérán, Olivier 41
 Vijayasingham, Lavanya 119
 Vives, Lauro 27
 von Baumbach, Hubertus 61
 von der Leyen, Ursula 51

von Kalle, Christof 49
 von Messling, Veronika 29
 Vorisek, Dana 47
 Voss, Maike 71

W

Waltz, Johannes 83
 Waqainabete, H.E. Ifereimi 91
 Wenham, Clare 99
 Were, Miriam K. 55
 Wieler, Lothar H. 31,41,65,73
 Wilson, Dow R. 81
 Winkler, Andrea 65,89
 Witty, Sir Andrew 29
 Wright, Caradee 75

Z

Zou'bi, Moneef R. 95

A

AO Alliance Foundation [90](#)
 Association of Academies and Societies of Sciences
 in Asia (AASSA) [74](#)
 Association of Research-based Pharmaceutical
 Companies (vfa) [82,114](#)

B

Berlin Institute of Health (BIH) [38,48](#)
 Boehringer Ingelheim Pharma GmbH & Co.KG [60](#)

C

Charité – Universitätsmedizin Berlin [38,42,78,112,124](#)

E

Eberhard Karls University Tuebingen [82](#)

F

Fondation Botnar [34](#)
 Foundation for Innovative New Diagnostics (FIND) [78](#)

G

German Alliance for Global Health Research [70](#)
 German Federal Ministry for Economic Cooperation
 and Development (BMZ) [64,106,116](#)
 German Federal Ministry for Economic Affairs
 and Energy (BMWi) [114](#)
 German Federal Ministry of Education and Research
 (BMBF) [62,70,72](#)
 German Federal Ministry of Health (BMG)
[66,100,120,128](#)
 German National Academy of Sciences Leopoldina
[88](#)
 German Network against Neglected Tropical Diseases
 (DNTDs) [82](#)

German Society for Tropical Medicine and
 International Health (DTG) [82](#)
 Germany's Presidency of the Council
 of the European Union [66](#)
 GHA – German Health Alliance [44](#)
 Global Antibiotic Research & Development Partnership
 (GARDP) [22](#)
 Global He@lth 2030 Innovation Task Force [122](#)
 Global Outbreak Alert and Response Network
 (GOARN) [108](#)
 Global Solutions Initiative [46](#)
 Global Young Academy (GYA) [126](#)

H

Helmholtz Centre for Infection Research (HZI) [26](#)

I

InfectControl [72](#)
 InterAcademy Partnership (IAP) [74,88,94](#)
 Inter-American Network of Academies of Science
 (IANAS) [74](#)
 International Atomic Energy Agency (IAEA) [80](#)
 International Federation of Medical Students' Associations
 (IFMSA) [76](#)
 International Federation of Pharmaceutical
 Manufacturers & Associations (IFPMA) [86](#)

J

Johnson & Johnson [28](#)

L

Leibniz Association [84](#)
 London School of Hygiene & Tropical Medicine (LSHTM)
[58,78](#)

M

M8 Alliance [30,50,56,58,78,94,110,112,124](#)
Max Delbrück Center for Molecular Medicine (MDC) [104](#)
Max Planck Institute for Infection Biology [42](#)
Medicines Patent Pool (MPP) [102](#)
Milken Institute School of Public Health [56](#)

N

NCD Alliance [92](#)

P

Program in Global Surgery and Social Change
of the Harvard Medical School [90](#)

Q

QUEST Center [38](#)

R

Research Center Borstel - Leibniz Lung Center [84](#)
Robert Bosch Foundation [36](#)
Robert Koch Institute (RKI) [108](#)
Roche [68](#)

S

Sanofi [40,92](#)
Sapienza University of Rome [110](#)
Siemens Healthineers AG [20](#)

T

Tehran University of Medical Sciences (TUMS) [56](#)
The BMJ [118](#)
The Defeat-NCD Partnership [60](#)
The George Washington University, Milken Institute School
of Public Health [56](#)
The Graduate Institute of International
and Development Studies [30](#)
The Lancet One Health Commission [64,88](#)
The Network of African Science Academies (NASAC) [74](#)

U

UNAIDS [44](#)
UNITE [44](#)
University Hospital Tuebingen [82](#)
University of Eastern Finland [32](#)
UNU International Institute for Global Health (UNU-IIGH) [118](#)

V

Varian Medical Systems [80](#)

W

Women in Global Health [98](#)
World Health Organization (WHO) [24,54,100,108,118,120,128](#)
World Health Summit [50](#)

SPONSORING PARTNERS

Strategic Partners



Der Regierende Bürgermeister von Berlin
Senatskanzlei
Wissenschaft und Forschung



Major Partners

Senate Department
for Economics, Energy
and Public Enterprises



General Partners



SUPPORTING PARTNERS



SERVICE PARTNERS



POLICY MAKERS



ACADEMIA



CIVIL SOCIETY



ASSOCIATES



MEDIA PARTNERS





WHS Foundation GmbH
c/o Charité – Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin
Germany

Tel.: +49 30 450 572102
Fax: +49 30 450 572911

contact@worldhealthsummit.org
www.worldhealthsummit.org

President

Detlev Ganten

Managing Director

Jörg Heldmann

Program Director

Julian Kickbusch

Strategic Communications Director

Daniela Levy

Director of International Cooperations

Nora Anton

Political Advisor

Reinhard Schäfers

Director of Operations

Petra Neitzel

Strategic Partnerships Officer

Lukas Pfannenschmidt

Media Assistant

Frederike Sontag

Content Assistant

Alida Tiekötter

PA to the President

Pascale Schulte

Office Manager

Martin Liedtke

Trainee

Wim Stavinski

The World Health Summit
is organized
in cooperation with:



With support from:



Photo Credits

Addo, Marylyn | Page 85 © C.D. Ketels
 Bachelet, Michelle | Page 121 © UN Photo-Manuel Elias
 Balasegaram, Manica | Page 23 © Laurent Egli
 Bethell of Romford, Lord | Page 87 © Roger Harris Photographie
 Beyer, Peter | Page 25 © Sunanda Deshapriya
 Bloom, Theodora | Page 39 © Philippa Gedge, 2017
 Bulmahn, Edelgard | Page 95, 139 © Deutscher Bundestag
 Capon, Tony | Page 89 © The University of Sydney/Louise M. Cooper
 Charmeil, Oliver | Page 41 © Peter Allan
 Cocero, Nanette | Page 51 © 2015, Wendy Barrows
 Colombo, Francesca | Page 21, 87, 99 © OECD/Andrew Wheeler
 Degos, Laurent | Page 125 © Laurent Hou
 Dirnagl, Ulrich | Page 21, 39 © BIH/Thomas Rafalzyk
 Doyle, Yvonne | Page 71 © Greater London Authority
 Draghia-Akli, Ruxandra | Page 43 © Merck & Co., Inc
 Drosten, Christian | Page 71, 79, 107, 125, 137 © Wiebke Peitz
 Eloit, Monique | Page 107 © Maurine Tric
 Flachsbarth, Maria | Page 65, 107, 117 © Thomas Trutschel/photothek.net
 Fore, Henrietta | Page 129 © UNICEF-UN0154449-Nesbitt
 Gantar, Tomaz | Page 67 © Bor Slana/STA
 Gastmeier, Petra | Page 73 © Wiebke Peitz
 Gore, Charles | Page 103 © CAP PHOTO
 Grossi, Rafael Mariano | Page 81, 121 © Dean Calma
 Guterres, António | Page 51 © UN Photo/Mark Garten
 Heyder, Ralf | Page 49 © Wiebke Peitz/Charité Universitätsmedizin Berlin
 Iyer, Jayasree | Page 29, 79, 103 © www.patriciawolf.nl
 Kieny, Marie-Paule | Page 37 © Inserm/Patrick Delapierre
 Klapper, Bernadette | Page 37 © www.michaelfuchs-fotografie.de
 Köhler, Carsten | Page 83 © UKT
 Kurth, Bärbel-Maria | Page 137 © Robert Koch-Institut/Dugnus
 Kurzai, Oliver | Page 73 © Anna Schroll
 Kyriakides, Stella | Page 55 © EU
 Merkel, Angela | Page 8 © Bundesregierung/S. Kugler
 Mettenleiter, Thomas | Page 73, 107 © Wolfram Maginot
 Müller, Jürgen | Page 41 © Kay Herschelmann
 Muhsin, Muhsinzoda Gafur | Page 101 © Ruziev

Mundani, Dagmar | Page 21 © W.Geyer
 Oelrich, Stefan | Page 87 © fotomanufaktur schnittfincke
 Ohnesorge, Bernd | Page 123 © Steffen Kirschner/Viaframe
 Ozawa, Sachiko | Page 115 © will kirk/the johns hopkins university
 Portella, Gennarina | Page 105 © Gianluca Cecere
 Rehfuess, Eva | Page 71 © Norman Pretschner
 Sands, Peter | Page 129 © The Global Fund/Vincent Becker
 Saso-Luciano | Page 111 © stephenbusuttil.com
 Schmutte, Caroline | Page 63 © Bernhardt Link/Farbtonwerk
 Sehouli, Jalid | Page 113 © Wiebke Peitz
 Seydoux, Stéphanie | Page 31 © Judith Litvine
 Shaikh, Majaheed | Page 37 © Vincent Mosch
 Stoffels, Paul | Page 29 © A.E. Fletcher Photography
 Stoltenberg, Camilla | Page 65 © Marius Tharaldsen
 Touraine, Marisol | Page 103, 129 © Elodie Grégoire
 Véran, Olivier | Page 41 © Ministeres Sociaux/DICOM/
 Nicola Revelli Beaumont/SIPA PRESS
 von Hirschhausen, Eckart | Page 139 © Camillo Wiz

Delphi-Saal | Page 134 © visitBerlin, Foto: Peter Gesierich
 Humboldtforum | Page 134 © SHF/visitBerlin, Foto: Stephan Falk
 Panorama Berlin | Page 135 © visitBerlin, Foto: Wolfgang Scholvien

Layout

Eta Friedrich, Berlin

Printer

Spree Druck, Berlin



World Health Summit

WHS Foundation GmbH
c/o Charité – Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin
Germany

Tel.: +49 30 450 572102

Fax: +49 30 450 572911

contact@worldhealthsummit.org

www.worldhealthsummit.org

SAVE THE DATES



WORLD HEALTH SUMMIT REGIONAL MEETING AFRICA

KAMPALA, UGANDA
JUNE 27-30, 2021

WORLD HEALTH SUMMIT

BERLIN, GERMANY
OCTOBER 24-26, 2021



www.worldhealthsummit.org
